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Cell surface glycans are branched structures composed of linear and branched 
chains of monosaccharides that include fucose. Fucose has important biological functions 
during ontogeny and cellular differentiation, suggested by pathological phenotypes 
observed in different strains of mice, including mice with a null mutation in the 3’, 5’-
epimerase/4’-reductase locus (FX-/- mice). FX-/- mice are conditionally deficient in all 
fucosylated glycans, and exhibit server thymic atrophy. This phenotype is cell autonomous 
and characterized by a fucose-dependent complete deficiency of mature T cell with loss of 
early thymic progenitors. Interestingly, Notch1 signaling deficient mouse models have been 
reported with the similar phenotypes, and there are reports that O-fucosylation is required in 
some in vitro experiments for Notch1 signaling. These results strongly suggested that lack 
of Notch1 signaling in FX-/- progenitors accounts for the thymic atrophy phenotype. By 
introducing the Notch1 intracellular domain into fucose-deficient FX-/- bone marrow-
derived lymphoid progenitors, the T cell developmental defect characteristic of FX-/- 
lymphoid progenitors is rescued and thus implicated a fucose-dependent requirement for 
Notch1 signaling in this process. In vitro, OP9 cells that are bearing Notch ligand of Delta-
like1 (Dll-1), Delta-like 4 (Dll-4) or Jagged2, instruct cells to assume a T lymphoid 
differentiation identity, whereas while OP9 cells bearing Jagged1 or Dll3 do not. However, 
in fucose-deficient experimental situation, FX-/- bone marrow cells fail to assume a T 
lineage identity when co-cultured with OP9-Dll1, OP9-Dll4 or OP9-Jagged2, and fail to 
initiate Notch1 signaling events. These results indicate that fucosylation is required for 
Notch1 signaling-dependent T cell differentiation. In effort to define the molecular 
mechanisms that account for fucosylation-controlled Notch1 signaling activation, I conclude 
 xi 
from a series of experiments that (1) fucosylation controls the strength of binding between 
Notch1 and its ligand Dll4, and (2) fucosylation controls Notch1 receptor density at the 
surface of an E2a/Pbx1 immortalized bone marrow progenitor cell line. These results 
indicate that fucosylation controls Notch1 signaling strength and thus regulates the 
development of T lymphocytes. My studies have revealed novel biochemical, cellular and 
developmental functions of fucosylation in the development and signaling pathways 




 Chapter I 
Introduction 
Although complex carbohydrate research began in the nineteenth centuries, it was 
not until the last fifty years that the field has received substantial experimental attention from 
biologists and biochemists. Together with nucleic acids, proteins, and lipids as the main 
components of biological system, complex carbohydrates are linear and branched chain 
sugar molecules found in most eukaryotic cells and organisms, including mammals, and are 
expressed through ontogeny to adulthood. Glycan structures vary in complex tissue-
specific and developmentally regulated expression patterns. At the molecular level, complex 
carbohydrates are primarily found covalently linked to proteins or to lipids, which has 
strongly suggested that sugar structures are involved in the regulation of biological systems. 
Recently, the term glycobiology has been used to refer to structure, biosynthesis and 
biology of saccharide chains that are widely distributed in nature (1). 
 The structures of glycans have been extensively studied with the emergence of 
modern analytic methods such as mass spectrometry. The basic unit of carbohydrates is 
called a monosaccharide that cannot be hydrolyzed into a simpler unit. These units include 
widely known sugar molecules like glucose, fucose and mannose. Monosaccharides in ring 
forms utilize potential carbonyl groups at the end of the carbon chain or at an inner carbon 
to be linked together. This results in the formation of oligosaccharides, comprised of linear 
and branched chains of monosaccharides. Polysaccharides usually refer to longer and more 
complex forms composed by multiple oligosaccharides. Unlike nucleic acids and proteins 
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that are composed of linear structures, glycans display enormous structural complexity and 
combinatorial diversity with combination of different branches (1). 
When polysaccharides are linked to a noncarbohydrate moiety (usually proteins), 
the resulting structures are termed as glycoconjugates. Glycoproteins are proteins with 
sugar molecules attached either in a N-linked or in an O-linked fashion. The most common 
form of polysaccharides on proteins are N-linked glycans, in which an N-acetylglucosamine 
(GlcNAc) is linked to some asparagine residues of membrane and secreted proteins (2, 3). 
O-glycans are linked to serine or threonine residues of proteins via typically N-
acetylgalactosamine (GalNAc) residues (4-6). They are also synthesized in the secretory 
pathway with diversification steps leading to linear and branched O-glycan structures (7). In 
addition to GalNAc, fucose, glucose and mannose may also be linked directly to come 
serine/threonine residues to form the base of other oligosaccharide during modifications (8-
10). 
Biosynthesis of glycoconjugates is typically associated with components of the 
protein synthesis pathway as occurs in different compartments of the cell (11, 12). The 
synthetic pathway contains not only elongations of the glycans but also modifications and 
even shortening. As one example, Figure 1-1a shows the synthesis of a branched N-linked 
glycan structure. This synthetic pathway of oligosaccharide assembly is highly ordered, so 
that each step shown is fully dependent on the previous one. Initially N-linked glycans arise 
in the endoplsmic reticulum (ER) of the early secretory pathway (13). A previously 
synthesized core structure containing of 14 monosaccharides including two GlcNAc, nine 
mannose residues and three glucose residues are added in a co-translational fashion to 
newly synthesized proteins. During maturation, three different enzymes, (glucosidase I, 
glucosidase II and ER mannosidase), modify the structure with cleavage of all three glucose 
residues and one mannose residue, resulting in a 10-unit structure. Up to this stage of 
protein synthesis, the variations of oligosaccharide structures are relatively limited. When 
synthesis moves into the Golgi lumen, more extensive modifications apply to the structure 
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resulting in very different structures depending on the set of enzymes expressed in a 
specific cell type (13, 14).  
One of the most well known O-linked glycan structure is shown in Figure 1-1b, as 
an example of linear oligosaccharides. The Epidermal Growth Factor (EGF) repeat is a 
component of many proteins and contains serine and threonine residues that are enzymes 
that may be covalently modified by a fucose molecule (15) by protein-O-fucosyltransferase 
1 (16, 17). The Fringe molecules are enzymes that catalyze the attachment of GlcNAc to O-
fucose (18). This glycan structure is further elongated by catalytic activities of β-4-Gal 
Transferase 1 (19) and either α-2,3-sialic acid transferase (shown in Figure 1-1b) or α-
2,6-sialic acid transferase (15, 18). This synthetic pathway is, like the biosynthesis of 
proteins characterized by a series of highly ordered linear single molecule additions.  
The structural characteristics of polysaccharides potentially allow them to carry 
more biological information than linear forms of nucleic acids and proteins (1). This is 
because that 1) polysaccharides are both linear and branched molecules, and 2) there are 
many distinct monosaccharides that contribute as components of polysaccharides. 
Nonetheless, the functional roles of glycans have remained enigmatic relative to the more 
extensively investigated nucleic acids and proteins. In the past decade, glycans have been 
discovered to serve as intermediates in protein folding (13) and cellular interactions (20), 
and as structural components of the cells and cell matrix (21). For example, alteration of 
glycosylation has been observed in cancer (22), ulcerative colitis (23), and cystic fibrosis 
(24). Recently, important functional roles have been ascribed to glycans in different 
signaling pathways. For example, O-fucosylated glycans have been shown to be involved in 
Notch signaling (25), which relates to many developmental process in mammals (26-29). 
However, it has not yet been shown if fucosylation is required for mammalian development, 
including the development of the immune system where Notch function is required (30, 31).  
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My thesis work emphasizes the novel physiological, cellular, and biochemical roles 
of fucosylated glycans in mammalian development, specifically in the development of T 
lymphocytes in the immune system. In this introduction a few key concepts, including the 
fucosylated glycans, Notch signaling and immune development, are briefly explained.  
 
Fucosylated glycans 
L-fucose, also known as 6-deoxy-L-galactose, is a monosaccharide commonly seen 
in many glycan structures from Drosophila to humans (32-35). The L-configuration and 
lack of a hydroxyl group on the carbon 6-position distinguish it from other small sugars. 
Fucose exits primarily as a terminal modification of N-glycans. Recent O-glycan structures 
have been found in which fucose is direct linked to serine/threonine residues (15). 
Numerous fucosylated glycan structures exist, and vary depending on the position of fucose 
added to proteins and/or oligosaccharides (Figure 1-2). N-linked fucose can exit as a 
terminal or subterminal modification of glycans.  O-linked fucose is directly added to 
proteins via serine or threonine residues. Like other monosaccharides, fucose is added to 
glycans or proteins by fucosyltransferases, enzymes that use GDP-fucose as the nucleotide 
sugar donor, linking to specific acceptors (Top of Figure 1-2). The catalytic domain of 
fucosyltransferases typically reside in the lumen of the Golgi lumen or endoplastic 
reticulum (ER) (36). Many fucosyltransferases display a pattern of tissue-specific 
regulation, suggesting important roles for fucosylated glycans in specific tissues or cell 
types.  
The biological significance of fucosylated glycans include the following: 
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(a) ABO blood group (37).  
The fucosyltransferase genes FUT1 and FUT2 encode the H transferase and the 
Secretor (Se) transferase, respectively. The H transferase is expressed in erythroid 
precursors while the Se transferase is expressed in epithelial tissues and salivary glands. 
They are both responsible for synthesis of a specific fucosylated glycan structure (H 
antigen) with fucose added in a "(1,2) fashion to the terminal galactose residue (Figure 1-
2). Humans whose red blood cells express only H antigen found are blood type O. H 
antigen can be modified further by the A transferase (an N-acteylgalactosaminyltransferase) 
or the B transferase (an galactosyltransferase) to form A or B antigen. Humans whose red 
blood cells express only A antigen are blood type A, while individuals with red cells bearing 
only the B antigen are blood type B. Blood type AB individuals have both A and B antigens 
on their red blood cells.  
Mixing blood from two individuals can cause blood clumping or agglutination. Big 
clumps of red cells can clog blood vessels and stop the circulation of the blood to various 
parts of the body. The clumped red cells may burst and its contents leak out in the body. 
Hemoglobin outside the cells becomes toxic to the body and resulted effects may be fatal. 
Thus, identification of an individual’s blood type is essential when blood transfusion is 
required. It’s necessary to ensure that blood transfusion recipients receive ABO compatible 
donor red cells. This compatibility study initiated the modern transfusion medicine. 
Lots of studies have shown the susceptibility of individuals with different blood 
types is different in many diseases. These studies include associations of blood type A with 
gastric cancer (38), blood type A and B with gastric atrophy (39), non-O group with 
increased severity of fibrosis in chronic hepatitis C infection (40), blood type O with low 
Factor VIII and von Willebrand factor expressed in blood that can lead to excess bleeding 
(41), non-O group with increased Factor VIII and von Willebrand factor expressed in blood 
that increase the risk of ischaemic heart disease and venous thromboembolic disease (41). 
For example, a bacteria strain of Helicobacter pylori is associated with the development of 
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gastritis, gastric ulcers and adenocarcinomas in humans. Bacterium Helicobacter pylori 
binds preferentially to Lewisb antigens found on the surface of gastric epithelial cells 
especially in stomach (42). Lewisb antigens are part of the blood group antigens that 
determine blood group O. However, the bacteria do not attach to the structure of blood type 
A antigen (42). Moreover, this result confirmed the epidemiological study decades ago that 
showed association of blood type O with gastric ulceration (43).   
(b) Host-microbe interaction. 
The microbial pathogen Helicobacter pylori can attach to host epithelial cells in the 
stomach by using a Lewisb glycan structure (determined by FUT2 and FUT3 product) 
(44). A and B blood group individuals have shown decreased peptic ulcer disease incidence 
that correlates with A antigen expression, which masks the fucosylated Lewisb structure 
(45). In mammalian experimental systems, overexpression of the FUT3 gene leads to 
Lewisb expression in non-Lewisb expressing cells, resulting in an increased severity of 
gastritis by Helicobacter pylori exposure (46).  Furthermore, the bacteria itself express the 
Lewisb structure and related glycans (47), and the expression of these structures increase at 
acid pH similar to the gastric environment (48). Taken together, these observations indicate 
that fucosylated glycans are important for host-microbe interactions.  
(c) Selectin-dependent leukocyte adhesion. 
Selectins are among the best-studied glycoproteins that are expressed on the cell 
surface. Three types of selectins have been found: P-selectin expressed on platelets and 
endothelial cells, E-selectin expressed by endothelial cells and L-selectin found on most of 
leukocytes (49). During the process whereby leukocytes are recruited from the vascular 
compartment to an inflammatory site, or in trafficking to lymph nodes, an initial step 
involves the deceleration of the rapidly moving leukocytes by a process called rolling, 
mediated by selectin and their counter-receptors, so that they may then firmly attach to the 
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endothelial wall of the vessels followed by migration to the extravascular compartment (49). 
Selectin ligands are modified with terminal fucose by the product of the FUT4 and FUT7 
fucosyltransferase loci, two "(1,3) fucosyltransferases (50, 51). Study of genetically 
engineered mice deficient in FUT4 and/or FUT7 demonstrate that "(1,3)-fucosylated 
glycans are essential for selectin-ligand interaction and related cell trafficking (52, 53).  
(d) Signal transduction in development. 
Fucosylated glycans are found on many proteins involved in cell signaling events 
during development. These include well-studied Notch receptors in Notch signaling (15), 
the cripto-1 receptor in Tumor Growth Factor (TGF)-beta signaling (54) and urokinase-
type plasminogen activator as a growth factor (55) in mammalian development. Fucose is 
added to these proteins in a O-linked fashion by protein O-fucosyltransferase 1 (16). This 
enzyme adds fucose directly to serine/threonine residues in epidermal factor like (EGF) 
domains (56). Abolishing fucosylated glycans of urokinase-type plasminogen activator 
inactivates its mitogenic activity without disturbing the cell surface binding ability (55). 
Inactivation of the protein O-fucosyltransferase 1 gene results in the absence of O-
fucosylated glycans on EGF domains, a failure of embryonic development (57), dysfunction 
of Notch signaling (58). Interestingly, absence of POFUT1 leaves cripto-related TGF-beta 
signaling intact (54). These observations indicate that fucosylated glycans play specific and 
essential roles in particular signaling pathways during development.  
 
Notch1 signaling pathway 
The Notch signaling pathway was first studied in Drosophila melanogaster and this 
pathway plays a role in lineage decision of neural precursor cells, directing them to become 
either neuroblasts or neuroepidermal cells (59-62). When Notch is overexpressed in 
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precursor cells, an increase of neuroepidermal cells has been observed at the expense of 
neuroblasts. By contrast, lack of functional Notch protein yields increased numbers of 
neuroblasts at the expense of neuroepidermal cells. These observations indicate that the 
Notch signaling pathway plays an important role in lineage decisions during development. 
Similar functions of the Notch signaling pathway have been demonstrated in other 
developmental systems.  
The Notch signaling pathway includes a family of highly conserved cell surface 
receptors (Notch proteins) on signaling receiving cells, and a set of structurally conserved 
cell surface ligands (Notch ligands) on signaling sending cells. In Drosophila, there is one 
Notch receptor, and two Notch ligands (Serrate and Delta). However, mammals possess 
four different Notch receptors (Notch 1, 2, 3, 4) and five different Notch ligands (Jagged1, 
2, Delta-like 1, 3, 4), suggesting much more complex regulations in mammalian species.  
Notch-dependent signal transduction is quite similar in flies and in mammals. As 
shown in Figure 1-5, mouse Notch1 is synthesized as a large polypeptide precursor, in 
ways similar to most cell surface transmembrane proteins that originate on the ER 
membrane. During this process, Notch1 receptors are also fucosylated on some serine and 
threonine residues. Fucosylated Notch1 proteins then move to the Golgi for further 
modifications. Within the Golgi, Notch1 proteins are cleaved by a Furin-like protease, and 
thus form heterodimer, and eventually are presented on the cell surface.  
Interactions between Notch and its ligand(s) are characterized by a series of 
subsequent proteolytic cleavages that are required for downstream signal transduction 
events. In Drosophila, the force applied by a Notch ligand to Notch extracellular domain 
(EC) has been shown to be essential to change the protein structure of Notch so that the 
ADAM (a distintegrin and metalloprotease) protease is recruited to cleave, and release the 
extracellular portion of Notch. Subsequently, #-secretase cleaves the Notch intracellular 
domain (Notch IC) at a site near or within the cell membrane. Notch IC, a 120 KD 
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polypeptide, then travels to the nucleus, where it displaces a transcriptional suppressor and 
then forms a multi-protein complex to initiate downstream gene expression. 
Unlike the MAP-Kinase signaling pathway, Notch signaling is without multiple 
cascades of protein phosphorylation and interactions before the downstream targets are 
transcribed in nucleus. Once Notch IC is cleaved from the anchored receptor, it directly 
travels into nucleus and the downstream genes are activated. There are few intermediates 
involved in the Notch signaling transduction pathway once the ICN is cleaved. However, 
many of the direct target genes activated by Notch are transcription factor genes, such as 
Hes-1 and Hes-6, which themselves are able to activate other target genes. These 
considerations imply that Notch signal transduction can yield very complicated gene 
activation cascades after direct targets were transcribed, and may affect as many as several 
hundred genes.  
Notch signaling has been implicated in many developmental processes, including in 
neurogenesis (26), somite formation (63), eye development (64),  inner ear and hair cell 
development (29), blood vessel formation (65), cardiogenesis (66), and very importantly, 
immune cell differentiation (67). For example, in fetal lung development, Notch signaling 
seems to be essential for lung size control, because losing Notch downstream target Hes1 
expression in mouse resulted in 20% decrease of lung size compared to wild type 
littermates (68). Jagged-mediated Notch signaling maintains proliferating neural progenitors 
and regulates cell diversity in the ventral spinal cord (69). 
Aberrant Notch signaling is associated with, or causes many diseases, including 
breast cancer (70),  lung cancer (71), and leukemia (72). Transgenic mice that ectopically 
express the intracellular domain of Notch4 (designated as INT-3) develop mammary gland 
tumors (73). A truncated transcript derived from the human Notch4 gene (h-Int-3sh) 
expressed in human breast cancer cell line of MCF-10A (74). These observations indicated 
the association of Notch4 to breast cancer.  
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A truncated Notch1, named as TAN1 (translocation-associated Notch homologue 1), 
is highly associated with T-cell acute lymphoblastic leukemia (T-ALL) patients, and formed 
by a chromosome translocation (75). TAN1 transduced mouse hematopoietic stem cells 
developed T-ALL after being transplanted in vivo (76), indicating its tumorgenic effects. 
Interestingly, immature TAN1 expressing T cells were found in the bone marrow, where 
they should not reside. These results indicate that the activation of Notch1 signaling 
promote T cell development. Conditional Notch1 knockout mice loss mature T cells in 
thymus (77), with B cell populations are enriched (78). These results suggested that the 
lymphoid progenitors adopt B cell fate in the absence of Notch1 signaling. Above 
observations indicated that Notch1 signaling plays an essential role in T lineage decision.  
Immune system and hematopoiesis 
The components of our immune system include cells within the bone marrow, 
thymus, spleen, lymph nodes, blood and the mucosal-associated lymphoid tissues (79). The 
bone marrow is the site of origination of the cellular components of immune system 
including B and T lymphocytes, and natural killer (NK) cells (80). The thymus is an organ 
located in the upper part of the mediastinum, behind the sternum, extending upwards into 
the root of the neck. The function of thymus is specialized for the development of T 
lymphocytes and other types of lymphocytes, which contribute to the adaptive immune 
system (81). The spleen is located in the upper-left part of the abdomen. It functions 
primarily to surveil for and collect antigens from the blood and to dispose of senescent red 
blood cells (82). Lymph nodes are located where the vessels of the lymphatic system 
converge. These secondary lymphoid organs contain both B and T lymphocytes that, 
together with dendritic cells, allow mammals to respond to foreign antigens (83). Blood 
enables the circulation of red cells and leukocytes, and delivers these cells, and protein 
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components of the immune system, including antibodies to lymphoid organs, and to sites of 
inflammation and antigen challenge (84).  
The developmental biology of the immune system includes hematopoiesis, the 
development of the cells of the blood (hematopoietic) cells (Figure 1-3). Different blood cell 
types are categorized by their shapes, cell surface markers, properties on staining, and by 
their functions. Hematopoietic cells develop from hematopoietic stem cells (HSCs) in the 
bone marrow (85). HSCs are capable of self-renewal, can differentiate into more mature 
cells, and can reconstitute the hamatopoietic system in of irradiated recipients (86). HSCs 
can be identified with cell surface markers by antibody staining, are negative for all mature 
lineage (Lin-) markers, and are positive for Sca-1 and c-Kit proteins (Sca-1+, c-Kit+) (87). 
Typically they are within a population of cells termed LSKs, standing for Lin-, Sca-1+, c-
Kit+. Long-term HSCs (Flt-3- LSKs) are capable of hematopoietic reconstitution for 
months after the bone marrow transplantation (88), while short-term HSCs (Flt-3+ LSK) 
are capable of conferring transient (a few weeks) bone marrow reconstitution (89). Both 
HSC populations are capable of generating all mature lineages including myeloid and the 
lymphoid cells (86, 90).  
Cells of the myeloid lineage are thought to derive from a common myeloid 
progenitor (CMP) derived from hematopoietic stem cells (91). These cells are lineage 
negative, IL-7 Receptor-alpha negative, Sca-1 negative, c-Kit positive, Fc-gamma receptor 
negative and CD34 positive (91). CMPs give rise to granulocyte/macrophage lineage-
restricted progenitors (GMPs) and megakaryocyte/erythrocyte lineage-restricted 
progenitors (MEPs) (91). GMPs and MEPs then differentiate into various specific cell 
types within the myeloid lineage, including monocytes and neutrophils (GMPs) and red 
cells and platelets (MEPs). 
Lymphocytes are a class of leukocytes that mediate the adaptive immune response 
involving antigen-specific reactions (79). In humans and mice, there are two main 
populations, B lymphocytes and T lymphocytes that share common lymphoid progenitors 
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(CLPs) in the bone marrow (92) (Figure 1-3). During lineage decisions in the lymphoid 
compartment, CLPs may be directed to assume a B lymphocyte phenotype in the bone 
marrow. Alternatively, CLPs and/or their later progeny may migrate out of bone marrow and 
develop into mature T thymocytes in thymus.  
Our knowledge of T lymphocyte development is extensive, yet still, incomplete. It is 
widely accepted that once T cell progenitors arrive in the thymus, they are instructed to 
progress through different developmental stages, beginning with a double negative (DN) 
phenotype (CD4- CD8a-), followed acquisition of CD4 and CD8a markers as the more 
mature double positive (DP) phenotype (Figure 1-4). Later, upon different selection signals 
provided by the thymic stromal cells, DP thymocytes will differentiate into one of two types 
of single positive (SPs, CD4+CD8a- or CD4-CD8a+) T cells, which are then exported to 
the blood stream, where the assure their immune functions. Our understanding of 
developmental processes in the thymus, blood, and marrow, proximal to the DN stage, is 
incomplete. 
 
Fucosylation, Notch signaling and the immune system 
Notch receptors are large proteins with 36 epidermal growth factor-like (EGF) 
repeats containing serine and threonine residues, some of which are modified by O-linked 
fucose, and extended O-linked fucosylated glycans (15, 18). In Drosophila, O-fucosylated 
glycans on Notch receptor are thought to be essential for Notch-dependent signal 
transduction (25). In mammalian cells, lack of O-linked fucosylation on Notch1 has the 
effect of reducing downstream signaling in the Notch pathways (58). These observations 
imply that fucosylation is important in Notch signal transduction.  
Notch receptors and Notch ligands are widely distributed in different cell types 
during hematopoietic development and differentiation (Figure 1-6). As Notch signaling is 
 13 
known to be critical for T cell development (77), it is very likely that O-linked fucosylation 
controls T cell development through modulating Notch1 signaling strength. Thus the 
important roles of fucosylated glycans in T cell development were hypothesized in this 
thesis. In principle, the hypothesis that O-fucosylation and T cell development are linked, 
could be examined by inactivating O-fucosyltransferase 1 in mice and ask if T cell 
developed in the animals. Unfortunately, as reported in 2005, POFUT1(-/-) mice are not 
able to grow to the age when T cells fully develop (57). 
In Dr. Lowe’s lab, a global-defucosylated mouse modal has been made in the effort 
to discover novel functions for fucosylated glycans, by deleting the locus encoding an 
enzyme termed FX (93). As I will described in subsequent chapters of this thesis, the FX(-/-
) mouse can be maintained as an essentially wild type animal when reared on water or chow 
supplemented with fucose, yet sustains a global fucosylation deficiency when the mice are 
reared without fucose supplementation. We observed a thymic atrophy phenotype in FX(-/-) 
mice in fucose-deficient environment, suggesting an important physiological role for 
fucosylated glycans in T cell development in these mice (discussed in Chapter 2). This 
hypoplastic thymic atrophy phenotype is very similar to the phenotype observed in mice 
subjected to inactivation of Notch1 signaling (77). These observations suggested that the T 
cell developmental deficiency characteristic of the fucose-dependent thymic atrophy 
phenotype in FX(-/-) mice is due to a fucosylation-dependent loss of Notch1 signaling in 
their T cell progenitors. Experiments in Chapter III indicate that Notch1 downstream 
signaling is indeed fucose-dependent, and that generation of mature T cells is fucose-
dependent. Moreover, biochemical and cell biology experiments reported in Chapter IV 
disclose that absence of O-linked fucosylation of Notch1 diminishes the ability of Notch 








Figure 1-1 Examples of glycan biosynthesis and glycan 
structures. a. N-linked oligosaccharide processing in the ER 
and the Golgi apparatus. (Molecular Biology of the Cell, 4th 
Edition, Alberts B and et al, New York and London: Garland 
Science; c2002) b. Structure of O-linked glycans on an 
Epidermal Growth Factor repeat. (Haltiwanger RS, Current 







Figure 1-2: Fucosylated glycans in Mammals. Structures of 
selected fucosylated glycans are shown here. N=number of 







Figure 1-3: Conceptual hematopoietic trees in adult mice. 
Indicated cell populations can be purified based on the cell 
surface phenotype. Not all of the linear relationships in this 
figure have been proven. Multipotent progenitors (MPPs), at 
least at the population level, can differentiate into all types of 
hematopoietic cells, but have no detectable self-renewal potential 
in vivo. (Kondo M, et al. Annual Review of Immunology Vol. 







Figure 1-4: Anatomical microenvironments in the adult 
thymus. The thymus is a lobed organ divided by mesenchymal 
septae. Lobes are organized into discrete cortical and medullary 
areas, each of which is characterized by the presence of 
particular stromal cell types, as well as thymocyte precursors at 
defined maturational stages. Thymocyte differentiation can be 
followed phenotypically by the expression of cell-surface 
markers, including CD4, CD8, CD44, CD25, CD69 and CD62L 
(Mel-14), as well as the status of the T-cell receptor (TCR). 
Interactions between thymocytes and thymic stromal cells are 
known to be important in driving a complex program of T-cell 
maturation in the thymus, which ultimately results in the 
generation of self-tolerant CD4+ helper and CD8+ cytotoxic T 
cells, which emigrate from the thymus to establish the peripheral 
T-cell pool. (4, CD4; 8, CD8; 44, CD44; 25, CD25; 69, CD69; 
TCRlow, expressing the TCR at low levels; TCRhi, expressing 
the TCR at high levels.) (Modified from Anderson G & 
















Figure 1-5: Notch expression and activation. Notch 
proteins are synthesized as a single peptide of ~300KDa. a. In 
the endoplasmic reticulum (ER), the Notch1 polypeptide is 
fucosylated by protein O-fucosyltransferase 1. b. Notch1 
protein is shuttled to the trans-Golgi, where it is cleaved by a 
furin-like protease (S1-cleavage) to generate the non-covalently 
bounded heterodimerized surface receptor. c. The Notch1 
heterodimer is on the plasma membrane where it is available to 
bind with its ligands on signal sending cells. d. The interaction 
with Notch ligand is induced by ADAM metalloproteinase 
TACE (S2 cleavage) close to the cell membrane. Notch1 
extracellular domain will get into signal sending cells by 
endocytosis. e. S2 cleavage is followed by mono-ubiquitylation 
of the intracellular portion of the transmembrane Notch 
fragment. f. This results in endocytosis of the transmembrane 
fragment of the Notch protein, presumably facilitating cleavage 
by #-secretase (S3 cleavage) on transmembrane portion. g. 
Intracellular Notch is released and translocated to nucleus, 
where it competes out binding of CSL to suppressor protein 
complex. After recruiting transcriptional co-activators, 
intracellular Notch1 induces downstream gene expression. 
Abbreviations: CoR (Co-repressor), CoA (co-activator). 
(Osborn BA and Minter LM, Nat Rev Immunol. 2007 Jan; 7(1): 


















Figure 1-6: Notch receptor-ligand expression during 
hematopoiesis in the mouse. Expression pattern of Notch 
receptors (above cells) and ligands (below cells) in different 
hematopoietic lineages in the organ of developmental origin: 
green, expressed genes; red, absence of detectable expression. 
Controversial results are not indicated unless a consensus has 
been reached. Abbreviations and references: N1!4, 
Notch1!Notch4; J1!2, Jagged1!Jagged2; D1,3,4, Delta1, 
Delta3, Delta4; BM, bone marrow; BM stromal; HSC; CMP, 
common myeloid progenitor; ELP, early lymphoid progenitor; 
Ery, erythroblast; Meg, megakaryocyte; Mono, monocyte; Mac, 
macrophage; Gran, granulocyte; DC, dendritic cell; myeloid DC; 
thymic DC; Mast, mast cell; proB, pro-B cell; preBI, pre-BI cell; 
preBII, pre-BII cell; Imm.B, immature B cell; Trans.B, transitory 
B cell; FoB; MZB; B1, B1 cell; NK, natural killer cell; ETP, 
early thymic progenitor; DN1!4, double-negative (CD4-CD8-) 
thymocyte subsets;  T,  T cell; DP, double-positive 
(CD4+CD8+) thymocyte; thymic CD4; CD4, CD4+ T cell; 
thymic CD8; CD8, CD8+ T cell; peripheral T; thymic stroma.  













As has been established in previous studies, glycoprotein fucosylation deficiency 
results in leukocyte adhesion deficiency (LAD) type II. This disease is a rare human 
congenital disorder resulting in developmental abnormalities, a deficiency of selectin-
dependent leukocyte trafficking and adhesion, and disabled O-linked glycan structure 
extensions in Notch receptors and thrombospondin repeat containing proteins. Mice 
genetically engineered with a mutation in FX locus, which encodes an enzyme controlling 
the last step in the de novo pathway for GDP-fucose synthesis, has global fucosylation 
deficiency, an extreme neutrophilia, myeloproliferation, and an absence of leukocyte selectin 
ligand expression. Furthermore, a severe thymic atrophy phenotype is observed in FX(-/-) 
mice, in temporal association with the loss of fucosylated glycan structures on soluble and 
cell surface proteins. However, restoration of fucosylation with a fucose-supplemented diet 
restores thymic development in the FX(-/-) mice within 2 weeks. In the FX(-/-) hypoplastic 
thymus, there is a loss of more than 95% of total thymocyte and mature T cells subsets 
(CD4+CD8a+, CD4-CD8a+, and CD4+CD8a-). Further, T cell progenitor populations, 
including the lineage negative DN2, DN3, and the recently proposed DN1a-b cells, are 
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absent in the FX(-/-) hypoplastic thymus after rearing the mice off fucose for 4 weeks. 
These observations strongly indicate that T cell development is disrupted in FX(-/-) mice in 
the absence of fucosylation. 
Introduction 
Leukocyte adhesion deficiency type II (LADII) is a rare human syndrome 
characterized by psychomotor defects, persistent leukocytosis, facial and skeletal 
abnormalities and developmental retardation (94). Cells from LADII patients display a 
global deficiency of fucosylated carbohydrate structures on the cell surface (95, 96). The 
molecular basis of LADII corresponds to a disruption in the de novo pathway of GDP-
fucose biosynthesis (Figure 2-1) (97).  
In this GDP-fucose synthetic pathway, GDP-fucose is the high-energy form of 
fucose and is used as a substrate in the synthesis of fucosylated glycans (44). In the de 
novo synthetic pathway, GDP fucose is converted first from GDP-mannose (98-100)  to an 
intermediate product, GDP-4-keto-6-deoxymannose, by the GDP-mannose 4,6-dehydratase 
enzyme (GMD) (Figure 2-1) (101). The sequence of GMD is substantially conserved 
among E.coli (102-104), mice (105) and humans (106, 107), suggesting that this synthetic 
pathway is essential for living organisms. The GMD mRNA transcript is expressed in 
almost all human tissues, although at considerably different levels (106), and has been 
detected in several human cell lines (107). Crystallography studies have shown that E.coli 
GMD protein belongs to the short-chain dehydrogenase/reductase family of proteins with 
threonine133-tyrosine-lysine catalytic triad and glucose135 as an active-site base (103). 
Crystallization and biochemical studies indicate that the GMD enzyme forms a domain-
swapped homodimer for intersubunit communication, with each monomer consisting of an 
NADP+ binding N-terminal domain and a GDP-mannose binding C-terminal domain (103, 
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107, 108). GDP-fucose, as a final product, inhibits the activity of GMD, which has been 
shown to function as a classic negative feedback in enzyme regulation (103, 104, 106-110).  
GDP-4-keto-6-deoxymannose is converted to GDP-fucose by a dual functional 
enzyme, 3,5 epimerase/4-reductase called FX (Figure 2-1) (111, 112). As an epimerase, FX 
speeds up the slow, spontaneous epimerization of the GDP-4-keto-6-deoxymannose stereo 
conversion to yield GDP-4-keto-6-deoxygalactose (113). The reductase activity of FX 
protein then catalyzes an NADPH-dependent transfer of a hydride to the keto group of 
GDP-4-keto-6-deoxygalactose to generate GDP-fucose (113). As first seen during the 
purification of glucose-6-phosphate dehydrogenase from human erythrocytes in 1975, FX 
was annotated as an NADP(H)-binding protein with unknown functions (114). It was not 
until twenty years later that FX was shown, by sequence comparisons to enzymes in the 
pathway for GDP-fucose synthesis in E.coli, to be involved in mammalian GDP-fucose 
synthesis (115). The FX locus has been highly conserved during evolution, with a 50% 
sequence identity between the human and E.coli enzymes, and with approximately 90% 
sequence identity among mammalian FX homologues (112). The structural study of the 
crystallized E.coli FX homologues assigns the FX protein to the reductase-epimerase super 
family (116). Somers and colleagues report a single substrate-binding pocket for GDP-4-
keto-6-deoxymannose in FX, indicating that the epimerization and reduction reactions take 
place at the same site (117). At 1.45-1.6 Angstrom resolution, X-ray crystallographic 
analysis of mutant E.coli FX molecules with site-specific changes in amino acid sequence 
identify Cys109 and His179 as components of the N-terminal NADPH-binding domain 
and a C-terminal domain that forms the substrate-binding pocket (118).  
After being synthesized in the cytosol, GDP-fucose is transported by a multi-pass 
transmembrane transporter to the lumen of the Golgi (119), where it is used for fucosylated 
glycan synthesis. O-fucosylation occurs in the ER (36) indicating the existence of a GDP-
fucose transporter in ER that transports GDP-fucose into the lumen of the ER (120). The 
catalytic domains of fucosyltransferases, as shown here residing in the Golgi lumen, direct 
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the GDP-fucose-dependent transglycosylation reaction that ultimately links fucose to 
specific acceptors (Figure 2-1) (44). Eventually, fucose-containing 
glycoconjugates/glycolipids are transported out of Golgi, to be presented on the 
extracellular side of the cell membrane, or to be released as a soluble molecule to execute 
their biological functions.  
Components of the de novo GDP-fucose synthetic pathway have been shown to be 
involved in many physiological and pathological pathways. The expression level of FX 
protein is elevated in human hepatocellular carcinoma/hepatocyte cell lines (121), in highly 
metastatic colorectal cancer variants (122), and in activated T and B cells (123). Further, 
synchronized upregulation of GMD, FX, GDP-fucose transporter and fucosyltransferase 
VII in inflammation and in tumorigenesis has been reported (124).  
Tonetti and colleagues first demonstrated that cells from LADII patients display a 
significant deficit in GMD activity (125). Thus those patients lack fucose-containing glycan 
structures and fucose-specific biological functions as reviewed in (126). The 
fucosyltransferases in LADII patients were expressed at normal levels (127), suggesting 
that the deficiency of fucosylation was due to the unavailability of GDP-fucose. Later it was 
shown that the GDP-fucose transport activity of Golgi preparations was reduced in cells 
from LADII patients (128, 129). Further, missense mutations (130) or deletion (131) found 
in locus of SLC35C1 gene, a GDP-fucose transporter protein on Golgi apparatus (132), 
corresponded to the LADII phenotype. Mice deficient in SLC35C1 displayed severe growth 
retardation, elevated postnatal mortality rate, dilatation of lung alveoli, hypocellular lymph 
nodes, and a deficiency of selectin-ligand function resembling the symptoms of LADII 
patients (133). Interestingly, adding fucose to cells from these SLC35C1 deficient mice 
partially rescued the phenotype, implying the existence of alternative mechanisms for 
transporting GDP-fucose into the Golgi lumen (133).  
These observations assign important roles to fucose and fucosylated glycans in 
physiology and pathogenesis. In order to uncover novel and specific functional roles for 
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fucose and fucosylated glycans, a genetically engineered mouse model was made in which 
the FX locus was disrupted to induce global fucosylation deficiency (112). Interestingly, 
FX(-/-) mice displayed a partially penetrate embryonic lethal phenotype, with the loss of the 
majority of embryos by 12.5 dpc (93). Intercrosses between FX(+/-) and FX(+/-) were 
carried out in an attempt to generate FX(-/-) mice. These intercross yielded only 6 live-born 
FX(-/-) mice, from a total of 360 progeny genotyped at weaning, which suggested that most 
FX(-/-) mice die in the uterus. These live-born FX(-/-) mice exhibit a postnatal failure to 
grow and have a life span of 1 to 2 months. These observations made it almost impossible 
to study the adult phenotypes of FX(-/-) mice on the original strain background.  
Fortunately, as will be elaborated below, a salvage pathway has evolved that allows 
the supply of GDP-fucose to be restored when the FX-dependent de novo synthetic 
pathway from GDP-mannose is disrupted (Figure 2-1), and was used in combination with 
breeding experiments to generate sufficient numbers of live-born FX(-/-) mice to study. The 
salvage pathway starts from free L-fucose molecules that are transported into cytosol from 
the extracellular milieu (121,134). Yorek and colleagues reported that the uptake of L-fucose 
in various mammalian cell lines is mediated by a fucose-specific process that is not 
receptor-mediated endocytosis but is characteristic of a facilitated diffusion system (135). 
They further purified the L-fucose transporter, a 57kD cell-membrane protein, from mouse 
brains (136). This transporter can be found in almost all major mouse tissues, such as the 
kidney, lung, spleen, heart, and thymus (136), suggesting that the GDP-fucose synthetic 
salvage pathway is not tissue-specific, but is instead a rather generally expressed pathway.   
In a two-step reaction, the salvage pathway in the cytosol converts exogenous L-
fucose. First L-fucose is phosphorylated by fucokinase, a 110kD protein that is widely 
distributed in mammalian tissues, to form fucose-1-phosphate (137-139). The only other 
sugar that can be phosphorylated by fucokinase is D-arabinose with the generation of "-D-
arabinose-1-P, at about 10% the rate of L-fucose, indicating the high specificity of this 
enzyme (138). Fucose-1-phosphate is subsequently converted to GDP-fucose by GDP-L-
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fucose pyrophosphorylase (128,129). This enzyme is a 61kD protein with specificity for 
beta-L-fucose-1-P, although it can use "-D-arabinose-1-P to produce GDP-"-D-arabinose 
(140). Similar to fucokinase, L-fucose pyrophosphorylase was widely distributed in all 
tissues tested (141), indicating that the salvage pathway is a universal mechanism for 
mammalian cell types. The activity of fucokinase and L-fucose pyrophosphorylase may 
change in various conditions, such as after the acquisition of a brightness discrimination 
reaction in the rat hippocampus (142), a day after passive avoidance training in chicks right 
forebrains (143), after incubation of dopamine with rat hippocampal slices (144), or by 
administrate rats with dopaminergic drugs in water (145). Although it’s not fully 
understood yet how fucokinase is regulated, L-fucose and its analogs inhibit fucokinase 
activity in vitro, indicating a negative feedback system similar to GMD (146).  
The degree to which the salvage pathway contributes to GDP-fucose synthesis 
under normal physiological conditions is not understood. In a quantitative study using in 
vitro HeLa cell culture, it has been observed that greater than 90% of GDP-fucose is 
generated from the de novo pathway in the presence of L-fucose (147), indicating a 
supporting role for the salvage pathway in GDP-fucose synthesis. However, this pathway 
may fully reconstitute cellular GDP-fucose levels in Chinese Hamster Ovary Lec13 cells, 
which lack GMD and are thus deficient for the de novo synthetic pathway (105), if L-fucose 
is added to the Lec13 cells in culture (Becker DJ & John Lowe, unpublished data).  
Taking advantage of the salvage pathway, fucose was added to the water or chow of 
two of the original FX(-/-) male mice. These FX(-/-) male founders, when reared on fucose, 
were found to be fertile, and when crossed with FX(+/-) females, gave rise to a nearly 
Mendelian ratio of progeny (50% -/-, 50% +/-expected, ~30%-/-, ~70% +/-) when the 
females were kept in cages with fucose supplementation (93). Breeding experiments further 
improved the yield of null progeny, which is essentially fully Mendelian when FX(+/-) 
males are crossed with FX(+/-) females, when the FX null allele is on a C57Bl/6J 
background (93).  
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Under these circumstances, FX(-/-) mice are able to grow to adulthood on fucose 
supplementation. Experimental evidence has shown that FX(-/-) mice on a fucose-
supplemented diet display an essentially wild-type phenotype in growth (by weight), 
viability (by survival analysis), and cellular functions (by histology and expression of 
fucosylated-glycans) (93).  
In addition, fucosylation is easily manipulated by simply supplying FX(-/-) mice 
with a fucose-containing diet, or maintaining the mice on water or chow not supplemented 
with fucose. Most experiments in my thesis were done using FX(-/-) mice fed with fucose 
from weaning until the age of 8 weeks. In some instances, these mice were then placed on a 
non-fucose supplemented diet, yielding fucosylation deficiency and the fucose-dependent 
phenotypes described previously (148). This approach to the conditional control of 
fucosylation makes it possible to observe phenotypes controlled by fucosylation in FX(-/-) 
mice. 
This chapter will focus on the thymic atrophy observed in adult FX(-/-) mice upon 
the withdrawal of fucose from their diet. Mature T cells were almost completely lost among 
total thymocytes isolated from these FX(-/-) mice. By phenotypic analysis of cell surface 
markers, T lymphocytes within the FX(-/-) hypoplastic thymus accumulated in an early 
stage of development. As discussed in the following chapters of this thesis, these 




Materials- All experiments were conducted in accordance with the National 
Institutes of Health guidelines for the care and use of animals and within the approved 
animal protocols of the University of Michigan and Case Western Reserve University 
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Animal Care and Use Committees. C57B/6 mice were obtained from Jackson laboratory. 
FX knockout mice, as FX(-/-), were made as previously described (93). FUT4/7 double 
knockout mice (DKO) were made, again, as previously described (53). Thymus was 
isolated from the mice and mechanically disrupted to make a single cell suspension. 
Thymocytes were first resuspended in red blood cell lysis buffer (Sigma) at room 
temperature for 5 minutes, and washed twice in Hank’s Balanced Salt Solution (HBSS, 
Gibco) with 0.1% Bovine Serum Albumin (BSA, Sigma) (working medium). Cells were 
pelleted by centrifugation and resuspended for cell counts by Trypan blue or phenotypic 
analysis by flow.   
Thymocyte enrichment- After red blood cell lysis, thymocytes were first incubated 
on ice for 10 minutes in HBSS+0.1% BSA with anti-mouse Fc block (1:400, BD 
Pharmingen). After being washed, the cells were then incubated on ice for 30 minutes with 
biotinylated antibodies from BD Pharmingen: anti-mouse CD3$ (553059), anti-mouse CD4 
(553045) (1mg/ml stock as 20ul/100x106 cells). The cells were then washed twice in 
HBSS+0.1% BSA and were incubated on ice for 15 minutes with rat-anti-mouse IgG 
magnetic beads (Miltyni Biotech) with a concentration of 120x106 cells/830ul beads. Then 
the bead-labeled cells were passed through magnetic columns for negative selection so that 
lineage positive cells were left bound on the columns. Cells that flowed through were 
collected for further surface antibody staining. In FX(-/-) mice rearing off fucose for 4 
weeks, this thymocyte enrichment procedure was typically skipped, since very few mature T 
cells were found.  
Flow cytometry- Thymocytes were stained with anti-mouse antibodies from 
eBiosciences and BD pharmingen and were incubated on ice for 30 minutes. Stained cells 
were then washed twice before being loaded into the cytometor for analysis. The following 
antibodies were used for CD4 and CD8a analysis and PSA staining: FITC-anti mouse 
CD4, PE-anti mouse CD8a, FITC-PSA (Pisum sativum agglutinin). As a negative control 
for lectin binding specificity, 100mM mannose was added in a staining medium of PSA 
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tubes. In lineage depleted DN1-4, ETP and DN1a-b analysis, biotinylated anti-mouse CD3, 
CD4, CD8a, CD11b, CD19, Gr-1, Ter-119, NK1.1 were first incubated with thymocytes on 
ice for 30 minutes. After being washed twice, cells were further stained with SA-PE-TxRd. 
Other antibodies used included APC-anti mouse CD44, APC-Cy7-anti mouse CD25, 
FITC- anti mouse CD24, FITC-anti mouse CD127 (IL7-R"), PE-anti mouse CD117 (c-
Kit). FACSAria (BD biosciences) FACScan (BD biosciences) and ELITE (Coulter) were 
used for 2-6 colored analysis. 
Bone marrow cells isolation- Bone marrow cells from femur and tibia of the mice 
were flushed out in HBSS with 0.1% Bovine Serum Albumin (tissue culture tested, Sigma). 
Red blood cells were lysed after isolation with red cell lysis buffer (Sigma). Lineage 
depletion was carried out by incubating the cells with biotinylated anti-mouse CD3, CD4, 
CD8a, %#-TCR, B220, Gr-1, CD11b, Ter-119, NK1.1  (BD, Pharmingen) antibodies, 
followed by magnetic bead depletion (Miltyni Biotec). 
Intravenous injection- Lineage depleted bone marrow progenitors were 
intravenously injected into FX(-/-) recipient mice off fucose for 4 weeks. 11x106 lineage 
depleted cells on average were isolated from one wild-type mouse and injected intravenously 
into a FX(-/-) recipient mouse off fucose for 4 weeks (12wks old). Recipient mice were 
analyzed four weeks after injection. 
 
Results 
Fucose depletion and abnormal FX(-/-) thymic development in an off fucose 
environment. 
Encouraged by previous evidence of the important roles of fucosylated glycan 
structures in the innate and adaptive immune systems (49), FX(-/-) mice were genetically 
constructed to uncover novel functional roles of fucosylated glycans (93). The de novo 
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GDP-fucose synthesis pathway was disrupted in the FX(-/-) mice by abolishing the 
function of the FX enzyme that controls the last step of the GDP-fucose synthesis (Figure 
2-1). As expected, FX(-/-) mice displayed a global fucosylation deficiency (93). In most 
cases, FX (-/-) mice mostly died around 12.5 days in the uterus, displaying the embryonic 
lethal phenotype. However, this lethality of FX(-/-) mice embryos was rescued by a fucose-
supplemented diet to mothers and the newborn babies. These FX (-/-) mice on a diet 
including fucose displayed wild-type phenotypes. As a result, there was no defect observed 
in these FX(-/-) “on fucose” mice and they were able to grow to adulthood (93). The size 
of the thymus of these FX(-/-) on-fucose mice was similar to their age-matched wild-type 
littermates, as shown in Figure 2-2. These observations indicate that by restoring 
fucosylation with a fucose-supplemented diet normal thymic development is sustained.  
After being fed with a fucose-supplemented diet until 8 weeks old, these FX(-/-) 
mice were fed on a non-fucose-supplemented diet to induce phenotypes that related to the 
loss of fucosylation (Figure 2-2 time bar). At a two-day interval, the thymus of FX(-/-) was 
isolated for analysis. The size of the FX(-/-) thymus decreased at the time of fucosylation 
loss and reached a steady state after 4 weeks off fucose (Figure 2-2). The size of the FX(-/-) 
thymus did not change when mice were maintained on a non-fucose supplemented diet for 
up to 13 weeks (data not shown).  
When FX(-/-) mice off fucose for 4 weeks were again fed a fucose-supplemented 
diet at two-day intervals, within two weeks the size of the thymus of these mice increased to 
a level comparable to that of their age-matched wild-type littermates, indicating that restoring 
fucosylation may fully rescue the atrophy phenotype in FX(-/-) mice.  
The number of total thymocytes of FX(-/-) mice dramatically decreased at the time 
of fucosylation loss and increased when fucosylation was restored, as shown in the same 
time frame of fucose supplementation to mice during analysis (Figure 2-2). Notably, as 
counted by trypan blue exclusion, when losing fucosylation for 4 weeks, the number of live 
total thymocytes of FX(-/-) mice dropped on average by a factor of 1000, from 1.38x108 
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(on fucose since birth, 12 weeks old) to 2.15x105 (4 week off fucose, 12 weeks old) (Figure 
2-2). These results indicate that one or more thymocyte populations were lost in FX(-/-) 
thymus off fucose for 4 weeks. In the following analysis, if not specifically indicated, 
“FX(-/-) off fucose” mice refer to FX(-/-) mice having been off fucose for 4 weeks.  
 However, FX(-/-) mice that had always been fed the fucose-supplemented diet had 
comparably sized thymuses (Figure 2-2) and comparable numbers of thymocytes (Figure 
2-3) relative to their age-matched wild-type littermates, indicating that the atrophy phenotype 
of FX(-/-) mice off fucose was not age-dependent. Rather, the atrophy phenotype of FX(-/-) 
thymus is only fucosylation-dependent.  
In our analysis, the fucosylation status of FX(-/-) thymocytes was monitored by the 
flow cytometry staining of P-lectin, also known as PSA (Pisum sativum agglutinin), which 
is a reagent that recognizes "(1,6)-fucosylated N-glycans (149) on the cell surface (93, 
150). PSA may bind to cells specifically and non-specifically. Free D-mannose can 
compete with fucosylated glycans on the cells and abolish the specific recognition of PSA 
to its fucosylated glycan target. Thus if PSA stains specifically on the cells, this binding can 
be abolished by adding D-mannose (data not shown) (93, 151). By 4 weeks off fucose, 
FX(-/-) thymocytes are mostly PSA negative, indicating the absence of fucosylated glycans 
on the cell surface and the fucosylation-deficient status of the thymocytes. When FX(-/-) 
mice off fucose for 4 weeks were again fed with a fucose-supplemented diet, the PSA 
positive thymocytes of these mice increased to 95% of their original total in two days, 
indicating the presence of fucosylated glycans on the cell surface and the fucosylation-
sufficient status of the thymocytes.  
It is interesting to notice that FX(-/-) thymocytes needed about 8 days to completely 
lose the "(1,6)-fucosylated N-glycans on their cell surface. However, in only 2 days, the 
"(1,6)-fucosylated N-glycans were detected again on FX(-/-) thymocytes. This time 
difference indicates that the fucosylated glycans may be turned over and fucose may be re-
used by the cells or the tissues of FX(-/-) mice; thus the fucosylated structures were still 
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being made in FX(-/-) thymocytes after a few days off fucose. These results also imply that 
the time frame from the synthesis of fucosylated structures to their presentation on the cell 
surface is about 2 days.  
These observations suggest that the thymic atrophy phenotype of FX(-/-) mice is 
fucosylation-dependent and reversible. We were particularly interested in understanding the 
mechanisms of this fucosylation-dependent thymocyte development, because in this way we 
might learn why and how fucosylation contributes to thymocyte development, a very 
important process in the formation of our adaptive immune system.  
 
The Complete Block of Mature T cell Development in FX(-/-) Mice off 
Fucose.  
The thymus is the organ in which T cell development occurs during the development 
of adaptive immune system. The total number of thymocytes include all T cells at various 
developmental stages within the thymus, thus they are very heterogeneous. CD4+CD8+ 
double positive (DP) cells compose 90% of the total thymocytes. We first tested whether 
this DP population was present in FX(-/-) off-fucose thymus by using two-parameter flow 
cytometry. Around 90% of cells in the thymus of a wild-type mouse were CD4 and CD8a 
double positive (Figure 2-4 a). However, FX(-/-) mice off fucose 4 weeks typically have less 
than 1% of DP cells (Figure 2-4 a). Instead, around 60% of FX(-/-) off-fucose thymocytes 
were in the CD4-CD8a- (DN) stage. CD4+CD8a- and CD4-CD8a+ (SP) cells in FX(-/-) 
off-fucose thymus were enriched up to 30% of total number of thymocytes. These results 
indicate that the missing DP population is probably the major defect in FX(-/-) off-fucose 
thymus and accounts for the thymic atrophy phenotype.  
Since there was a dramatic change in the total thymocyte number of FX(-/-) off-
fucose mice, the percentage of each population could not represent the change in number 
within the thymus. The numbers of DP, DN and SP populations were further enumerated 
by multiplying the percentage of each population with the total thymocyte number (Figure 
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2-4 b). The numbers of CD4+CD8a+ DP, CD4+CD8a-, and CD4-CD8a+ cells were graphed 
according to the time frame shown in Figure 2-2. Similar to the changes of total thymocytes, 
the numbers of all of these mature thymocyte populations in FX(-/-) mice first decreased 
upon the time of fucose depletion. FX(-/-) mice off fucose 4 weeks had only 3.03x103 DP 
cells in average, while FX(-/-) on-fucose littermates had 1.21x108 DP cells on average, and 
age matched wild-type mice had 1.47x108 DP cells on average. Despite the enrichment of 
SP populations, as shown by percentage in Figure 2-4 a, the numbers of CD4+CD8a- and 
CD4-CD8a+ cells in FX(-/-) off-fucose thymus actually decreased during fucose depletion, 
indicating that the maturation of T cells is abolished upon the time of fucosylation loss in 
FX(-/-) mice. 
When fed with a fucose-supplemented diet, FX(-/-) mice had an increase in all these 
mature thymocytes and reached levels comparable to their 14-week-old wild-type littermates 
(Figure 2-4 b). These results indicated that the generation of mature thymocytes could be 
restored by fucosylation.  
 
Lin- DN1 T Cell Progenitors Missing in FX(-/-) Mice off Fucose.   
Loss of mature thymocytes in FX(-/-) mice on a non-fucose supplemented diet 
strongly indicated a “block” during thymocyte development. Most of the thymocytes in the 
FX(-/-) off-fucose thymus were in the CD4-CD8a- (DN) stage, which is earlier than the DP 
and SP stages. To further refine the developmental stages within DN cells, CD44 and CD25 
were used to divide the CD4-CD8a- cells into four different stages (152-154). 
CD44+CD25+ (DN1) cells within DN population progress through CD44-CD25+ (DN2), 
CD44-CD25+ (DN3) to CD44+CD25- (DN4), and then up-regulate CD4 and CD8a 
expression to be DP cells as a traditional model for T cell development. FX(-/-) mice off 
fucose 4 weeks had in average 76.51(±0.53)% of CD4-CD8a- cells in CD44+CD25- (DN1) 
stage of the T cell developmental pathway (data not shown), which indicated a possible 
accumulation of T cell progenitors. However, within the DN1 population, other lineage 
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positive cells, including B cells as B220+CD19+ and NK cells as NK1.1+, were found (155, 
156) (data not shown). These observations indicated that lineage positive cells should be 
excluded in the analysis of T cell progenitors that usually don’t express any of the lineage 
markers. A previous study indicated that B220 is also expressed on T progenitors in 
addition to B cell progenitors (157). To avoid the depletion of this potential T progenitor 
population, CD19 was used as a marker for mature B cells in our analysis, while in other 
studies B220 might be used during lineage depletion (157-159). 
The DN1 population is thus extremely heterogeneous, and we analyzed the T cell 
progenitor populations after excluding mature hematopoietic cells. Wild-type thymocytes 
and FX(-/-) on-fucose thymocytes usually occur in the range of 108 per thymus, and lineage 
negative thymocytes were enriched by passing them through the columns that bind to 
magnetic beads conjugated on lineage positive cells. Due to the very limited cell numbers of 
FX(-/-) off-fucose thymus, lineage depletion was carried out simply by electronic gating 
during analysis without lineage depletion by magnetic columns. In fact, around 8 to 10 
thymuses of FX(-/-) off fucose for 4 weeks were combined to generate one flow profile in 
each analysis.  
Propidium iodide (PI) was used at a final concentration of 1ug/ml in every staining 
tube in order to separate the live cells from the dead, because it can stain nuclear chromatin 
when cell membrane is disrupted (160). Live FX(-/-) thymocytes were electronically gated 
on PI negative staining first, and then lineage negative (Lin-) cells were analyzed by CD44 
and CD25 surface markers to be grouped as Lin-DN1 to Lin-DN4 cells (161). Compared 
with age-matched FX(-/-) on fucose and wild-type thymocytes, Lin-DN2 and Lin-DN3 cells 
greatly decreased. 60% of lineage negative FX(-/-) mice off-fucose thymocytes were in the 
Lin-DN1 stage, while 40% of them were in the Lin-DN4 stage (Figure 2-5 a). Although 
there seems to be an accumulation of Lin-DN1 cells in FX(-/-) off-fucose thymus 
percentage-wise, the numbers of the FX(-/-) off-fucose Lin-DN1 cells actually decreased 
(Figure 2-5 b). The complete absence of Lin-DN2 and Lin-DN3 cells in FX(-/-) off-fucose 
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thymus suggests that there is a “block” during the transition of the DN1 stage to the DN2 
stage in early thymocyte development. The presence of Lin-DN4 cells in the FX(-/-) off-
fucose thymus and the absence of DP cells that are a direct downstream population of Lin-
DN4, indicate that there is another “block” during the transition from the DN4 stage to the 
DP stage. These multiple “blocks” suggest that fucosylation is required in all stages of 
early T cell development.  
 
Early T Cell Progenitors Missing in the FX(-/-) Off-fucose Thymus 
Interestingly, Lin-DN1 cells are also very heterogeneous. These cells do not equally 
express cell surface markers such as CD117 (c-Kit), CD127 and CD24, according to the 
studies that attempted to define the earliest thymic immigrants (158, 159, 162).  
Bhandoola and colleagues proposed ETPs (early T cell progenitors) defined as Lin-
CD117+CD127-DN1, which represented a very small population of thymocytes, giving rise 
only to T cells or B cells in vivo (158). In their studies, ETPs were the major population, 
87% (158) or 69% (162) within lin-DN1 cells, however in our study we typically found that 
3% of Lin-DN1 cells were ETPs (Figure 2-6). The difference might depend on the different 
definitions of lineage negative/low populations during analysis with the obscure standards 
in history. Another possibility is that the CD19 marker is used in our analysis to include 
B220 positive T cell progenitors, which is different from others (157-159), since previous 
studies have shown that B220 may be expressed by T cell progenitors (157). Compared to 
wild type and FX(-/-) on-fucose littermates, the ETP population was missing in FX(-/-) mice 
off fucose for 4 weeks (Figure 2-6).  
In another study, Petrie and colleagues proposed five different populations within 
lineage negative DN1 cells defined by the surface CD24 and CD117 expression. Among 
these five different populations, DN1a-b were the T cell progenitors (159). However, the 
DN1a and DN1b populations could not be fully separated in our analysis (Figure 2-7) nor 
in Bhandoola’s study (162). DN1a-b cells may generate only T cells in vitro (159), and T 
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and B cells in vivo (162). Petrie’s group found around 12% of Lin-DN1 cells were in the 
DN1a-b stage (159), while Bhandoola’s group found 69% Lin-DN1 cells are DN1a-b cells 
(162) by using the same analytical method. Thus, there is an inconsistency in the literature 
regarding the percentage of DN1a-b cells per thymus, which may possibly be due to the 
lineage negative gating. In our study, we consistently found that 2% of the lineage negative 
DN1 cells were in DN1a-b stages in wild-type thymocytes.  
In their study, Bhandoola and colleagues further proposed that ETPs are the same as 
DN1a-b cells (162). Our results, that similar percentages of ETPs and DN1a-b cells were 
found in lineage DN1 thymocytes, seem to be consistent with this proposal. Similar to the 
result of ETP analysis, the DN1a-b population was missing to a large extent in FX(-/-) off-
fucose mice (Figure 2-7). To some extent DN1c and DN1d were also missing in FX(-/-) 
off-fucose thymus, and to some extent DN1e was enriched.  
These results suggest that early T cell progenitors could not develop or survive in 
the FX(-/-) off-fucose thymus. These observations also suggest that early T cell progenitors 
may not be able to get into the FX(-/-) off-fucose thymus. To answer these results raised, 
we further analyzed several possible reasons for the FX(-/-) thymic atrophy. 
 
Proposed Causes of FX(-/-) Thymic Atrophy: 
1. Notch1 signaling deficiency 
Notch1 conditional knockout mice were reported with a thymic atrophy phenotype 
similar to FX(-/-) off-fucose mice (77). Most of the cells lost in Notch1 knockout mice 
were mature DP thymocytes, which is very similar to the observations in FX(-/-) mice. 
Further, the DN1a-e populations observed in the FX(-/-) hypoplastic thymus are very 
similar to the DNMAML1 (Dominant negative mastermind like molecule-1) transduced 
bone marrow cells in the bone marrow transplantation experiments (162). In this study, a 
dominant negative form of MAML1 was introduced into the bone marrow progenitors, in 
order to compete out functional MAML1, a transcription co-activator required in Notch1 
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signaling (163). Progenitors with inactivation of Notch1 signaling populated the thymus in 
vivo with an enriched DN1e population and, most importantly, with an absence of DN1a-b 
populations (162). These observations suggest that the thymic atrophy of FX(-/-) off-fucose 
thymus is due to the disruption of Notch signaling.  
 
2. Thymic Environmental Defects. 
T cell development occurs only within the thymus of mammals, indicating the 
thymic environment is unique for T lineage commitment. Another possibility is that the 
FX(-/-) off-fucose thymic environment may not be capable of supporting T progenitor 
development. Defects in the thymus epithelial cells could result in the reduced production of 
T cells (164). To identify whether the thymic environment of FX(-/-) off-fucose mice can 
support T cell development, the developmental potential of healthy bone marrow stem cells 
from wild-type mice were tested. Lineage depleted donor bone marrow cells isolated from 
one wild-type mouse (11x106 cells in average, with CD45.1 expression) were injected 
intravenously into an FX(-/-) (CD45.2) recipient mouse that had been off fucose for 4 
weeks (Figure 2-8a). The chimera mice were analyzed 4 weeks after the bone marrow 
transplantation (165).  
The total number of thymocytes in the recipient mice (1.20 x108 /thymus in average 
of 6 mice, 3 independent experiments) was found comparable with age-matched wild-type 
mice (14 weeks old, 1.39x108/thymus in average of 6 mice). The wild-type donor-derived 
CD45.1+ cells were the major population (96%) in the recipient thymus and were PSA 
positive (Figure 2-8b). Around 96% of CD45.1+ donor derived thymocytes were DPs, 
which was comparable to the wild-type mice (Figure 2-8).  
CD45.2+ endogenous cells were PSA negative (Figure 2-8b). The absence of 
fucosylated glycan structures on recipient cell surfaces indicated that there was no fucose 
transfusion from donor cells to recipient cells. Phenotypically, CD45.2+ endogenous cells 
remained in the DN stage, which was similar to the mock-injected recipients (data not 
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shown) or age-matched FX(-/-) mice off fucose (Figure 2-8). The absence of the DP 
population in the recipient endogenous thymocytes indicates that donor cells did not alter 
the development of recipient cells. 
These results indicate that wild-type healthy hematopoietic cells develop to mature T 
cells when fucosylation is absent in the thymic environment; thus the fucosylated thymic 
environment is dispensable for T cell development. These results suggest that the thymic 
atrophy in FX(-/-) mice off fucose is cell-autonomous.  
 
3. Thymic Progenitor Homing Defects. 
Due to the absence of ETPs in FX(-/-) off-fucose thymus, one possibility is that the 
fucose-deficient thymocyte progenitors may not home to thymus. It has been reported that 
bone marrow cells losing P-selectin glycoprotein ligand 1 (PSGL-1) showed defective 
thymocyte homing ability in competition with wild-type thymocytes (166). PSGL-1 is a 
heavily glycosylated protein with alpha-1,3 fucosylated moiety required for its normal 
functions (167) that binds selectively to P-selectin (168, 169) and E-selectin (170, 171). It 
contributes greatly in the leukocyte and neutrophils rolling process (172, 173). 
Fucosyltransferase 4 and 7 are in charge of adding terminal fucose to functionalize PSGL-1 
(174) and play important regulatory roles in leukocyte rolling (52, 53). Thus FUT4/7 
double knockout mice lack functional PSGL-1 and mimic the major phenotypes of PSGL-1 
knockout mice. However, neither FUT4/7 double knockout mice nor PGSL-1 knockout 
mice have thymic developmental abnormalities, indicating that PSGL-1 and alpha-1,3 
fucosylated glycans are dispensable for thymocyte homing and development (52, 53, 166). 
Thus the defective homing is apparently not the major reason for FX(-/-) thymic atrophy.  
 
4. Increased Apoptosis.  
Another reason for the FX(-/-) thymic atrophy may lie in the increased apoptotic 
events in thymocytes. Apoptotic DP thymocytes were found throughout the cortex region of 
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the normal thymus and were thought to correspond to the consequences of positive and 
negative selection (175). If apoptosis is the main reason for the loss of DP cells in FX(-/-) 
thymus, the apoptotic events have to happen before the DP stage. To address this 
possibility, lineage negative DN1 cells were stained by Annexin V, a reagent detecting early 
apoptotic cells (176). Thymic early progenitors of 4-week off-fucose FX(-/-) mice showed a 
similar percentage of apoptotic cells (Annexin V positive) within Lin-DN1 and other 
populations, as the age-matched littermate FX(-/-) on-fucose mice and the age-matched 
wild-type mice (data not shown). These results indicate that the decrease in the total 
thymocytes is not likely due to the apoptosis of FX(-/-) thymic progenitors off fucose. It 
could be possible that early T cell progenitors undergo apoptosis at such a high rate that we 
cannot detect their presence within the thymus.  
To summarize the above analysis, the deficiency of multiple populations of T cells 
and their progenitors in FX(-/-) off-fucose thymus indicates that the normal thymocyte 
development pathway is disrupted. Of the above possibilities, it is most likely that this 




The results presented here described a novel phenotype of FX(-/-) mice in the 
function of fucosylation. It was very interesting for us to find out how fucosylation and/or 
fucosylated glycans control thymocyte development, which is an important process during 
immune system development. The enumeration of total thymocyte numbers of FX(-/-) off-
fucose mice indicates that there were populations missing within the atrophic thymus. In 
order to find out which populations were missing in FX(-/-) off-fucose thymus, almost all 
known populations within the thymocyte developmental pathway, such as DP, SP, DN, Lin-
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DN1-4 and early thymic progenitors, were analyzed. This analysis was our first step in 
determining the mechanism of FX(-/-) off fucose thymic atrophy.  
 
No Thymic Atrophy Reported in Known Fucosyltransferase Deficient Mice. 
FX enzyme controls the total de novo production of GDP-fucose, the substrate of all 
the fucosyltransferases. Disruption of GDP-fucose synthesis in vivo ablates the supply of 
GDP-fucose as the substrate for all of the fucosyltransferases (FUT) and disrupts all the 
functions of the fucosyltransferases. In theory, FX(-/-) mice display all the phenotypes that 
could be found in fucosyltransferase deficient mice.  
Glycans synthesized by fucosyltransferases contribute to many different 
developmental, physiological, and pathophysiological processes, such as ABO blood type 
(by FUT1 and FUT2 gene products) (37), host-microbe interactions (e.g. by FUT2 and 
FUT3 gene products) (45), selectin-dependent leukocyte adhesion (by FUT4 and FUT7 
gene products) (52, 53) and neonatal development (e.g. by FUT9 gene product) . So far, 13 
fucosyltransferase genes have been identified in the human genome, FUT1, FUT2, FUT3 
(177), FUT4 (178, 179), FUT5 (180), FUT6 (181, 182), FUT7 (183, 184), FUT8 (185), 
FUT9 (186), FUT10 and FUT11 (187-189), OFUT1 (17), and OFUT2 (188).   
Among these fucosyltransferases, FUT10 and FUT11 are putative 
fucosyltransferases based on sequence comparisons only and as yet have unknown 
functions and no known enzymatic activities. The remaining genes are grouped by the 
glycan structures they make: "-1,2 FUT (FUT1 and FUT2), "-1,3 FUT (FUT3,4,5,6,7 and 
9), and "-1,6 FUT (FUT8) and O-FUT (OFUT1 and OFUT2). Mice deficient in FUT1, 
FUT2, FUT4, FUT7, FUT8, or FUT9 have no reported thymic developmental defects (53, 
190-192). FUT3, FUT5, and FUT6 are clustered in the human genome (193) but do not 
have functional homologues in mice (194, 195). FUT9 product CD15 has no expression in 
adult thymocyte subsets and LSKs in mice (Yunfang Man & John Lowe, unpublished 
data). In summary, the absence of genes accounting for constructing N-fucosylated glycans 
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does not result in thymic atrophy. It seems that N-fucosylated glycans may not play a role 
in thymic development.  
In recent studies, OFUT1 and OFUT2 were found encoding enzymes with O-
fucosylation abilities that add fucose directly to EGF repeats or thrombospondin type I 
repeats (TSRs) respectively (17, 196, 197). Recently, Protein O-fucosyltransferase 
(POFUT) 1 has been extensively studied for the important role it plays in Notch signaling 
in Drosophila (25) and mammals (58). OFUT1 knockout mice display the embryonic lethal 
phenotype and most of the mice die on day 8 of postgastrulation, strongly indicating the 
important role of O-linked glycans in early developmental stages (57). POFUT2 adds 
fucose specifically to the TSRs of many important proteins (196), and mice lacking 
POFUT2 also die early in embryo (Lowe, Haltiwanger, unpublished  data). Thus, it is not 
known yet whether POFUT1 or POFUT2 regulates adult thymic development. 
 
O-fucosylation (Notch signaling) May Contribute to FX(-/-) Thymic 
Atrophy 
GDP-fucose is added to different glycans as a terminal modification in Golgi or 
directly to the Serine/Threonine of proteins in ER. Most fucosyltransferases seem to reside 
in Golgi except POFUT1 found in ER. It’s not known yet if POFUT2 resides in ER. Thus 
we could ask whether the FX(-/-) thymic atrophy relates to ER fucosylation or Golgi 
fucosylation. 
Mice lacking the Golgi GDP-fucose transporter SLC35C1 do not have N-
fucosylated glycans, since GDP-fucose cannot get into Golgi. Since transportation of GDP-
fucose to ER is not disrupted, SLC35C1(-/-) mice have ER O-fucosylated glycans 
expressed with their normal functions. In other words, SLC35C1 deficient mice are 
considered to resemble a putative mouse model with all fucosyltransferase genes knocked 
out but with OFUT1 left intact. FX(-/-) mice are considered to have all fucosyltransferases 
genes knockout out due to the global fucosylation deficiency. Thus in theory the phenotype 
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differences of FX(-/-) mice and SLC35C1 mice should represent the functions of O-
fucosylation.  
However, thymic atrophy was not observed in SLC35C1 mice but was a major 
phenotype for FX(-/-) mice. This strongly indicates that thymic atrophy is due to a lack of 
O-fucosylation in FX(-/-) mice. As it has been reported, O-fucosylation is critical for Notch 
signaling, which regulates thymic development. Finally then, we reach the hypothesis that 
the FX(-/-) thymic atrophy phenotype is due to a lack of O-fucosylation and results in 
Notch signaling deficiency. 
This hypothesis initiates the study to confirm the contribution of Notch signaling in 
FX(-/-) thymic atrophy in vivo and in vitro, as described on the cellular level in Chapter III. 
Chapter IV further pursues, using the methods of biochemistry, the mechanism of how 
fucose contributes to Notch signaling. 
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Notes to Chapter II 
 1Acknowledgments: We thank Peter Smith for advice on phenotype analysis. 
  
2Attribution of data: Jay Myers performed the thymus dissection depicted in Figure 
2-2 and contributed to Figure 2-5, Figure 2-6 and Figure 2-7. Clare Rodgers 







Figure 2-1 Fucosylation pathways in mammals. Two 
different cytosolic pathways lead to formation of GDP–fucose. 
The constitutively active de novo pathway converts GDP–
mannose into GDP–fucose via oxidation, epimerization, and 
reduction catalyzed by two enzymes (GMD and FX). The 
salvage pathway initiates with free fucose, delivered to the 
cytosol from extracellular sources (shown) or from intracellular 
(lysosomal) sources (not depicted). (Smith PL, et al, The 






















Figure 2-2 Thymic atrophy and total thymocyte decreased 
in FX-/- mice upon the time off fucose. Each bar shows the 
average of 3 and more animals while N=37 on FX-/-off fucose 












Figure 2-3 FX-/- on fucose mice have normal thymic 
development. N> or =3 for each data point. Error bars 
















Figure 2-4 Mature T cells greatly decreased in FX(-/-) 
thymus. a. CD4+CD8a+. CD4+CD8a-, and CD4-CD8a+ 
subsets of cells in FX(-/-) total thymocytes decrease upon the 
time off fucose in FX(-/-) mice. N>=3 for each data points. 
N=37 for off fucose 4 weeks.  Error bars show SEM. b. 
Representative flow cytometry data of 3 or more experiments on 












Figure 2-5 Lineage negative DN1-4 cells. Top panel shows 
the representative flow profiles of 4 individual mice in 3 
different experiments. CD44 and CD25 on lineage negative, PI 
negative thymocytes. Lin-DN1: Lin-CD44+CD25- (lower right 
population), Lin-DN2&3: Lin-CD25+ (upper population) Lin-
DN4: Lin-CD44-CD25- (lower left population) Bottom panel 
shows the numbers per thymus of each DN subsets of different 
ages and genotypes. Each bar shows the average of 4 mice, with 









Figure 2-6 Early T cell progenitors. Top panel shows the 
representative flow profiles of 4 individual mice in 3 different 
experiments. CD127 and CD117 (c-Kit) on lineage negative, PI 
negative DN1 thymocytes. ETP: Lin-DN1CD127-c-Kit+ Bottom 
panel shows the numbers of ETPs per thymus of different ages 








Figure 2-7: DN1a-b T cell progenitors. Top panel shows the 
representative flow profiles of 4 individual mice in 3 different 
experiments. CD24 and CD117 (c-Kit) on lineage negative, PI 
negative DN1 thymocytes. DN1a-b: CD24+CD117+ Bottom 
panel shows the numbers of DN1a-bs per thymus of different 










Figure 2-8: Cell autonomous defect in FX(-/-) hypoplastic 
thymus. FX(-/-) off fucose thymic epithelial cells and soluble 
cytokine are taken together as “thymic environment in the 
absence of fucosylation” tested by intravenous injecting wild 
type bone marrow cells (Top panel). Four weeks after bone 
marrow transplantation, donor (CD45.1) and recipient (CD45.2) 










Dysfunction of Notch1 signaling in pathogenesis of  
FX(-/-) thymic atrophy 
Abstract 
FX(-/-) mice lacking the de novo fucose synthesis pathway displayed a severe cell 
autonomous thymic atrophy, with a loss of multiple mature thymocyte populations. This 
phenotype is very similar to that reported in Notch1 conditional knockout mice, and thus it 
is very likely that the Notch1 signaling pathway is disrupted in FX(-/-) mice. To test this 
hypothesis, the Notch1 intracellular domain was introduced into fucose-deficient FX(-/-) 
bone marrow-derived lymphoid progenitors, and the cells were assayed for T lymphoid 
developmental potential. This experimental maneuver rescued the T cell developmental 
defect characteristic of FX(-/-) lymphoid progenitors and thus implicated a fucose-
dependent requirement for Notch1 signaling in this process. In vitro, when genetically 
modified to express some Notch ligands, a bone marrow-derived stromal cell line termed 
OP9 can support the generation of the T-lymphoid lineage from bone marrow stem cells, 
providing another platform to test our hypothesis. OP9 cells bearing the Notch ligands 
Delta-like1 (Dll-1), Delta-like 4 (Dll-4) or Jagged2, when co-cultured with WT bone 
marrow stem cells, instruct such cells to assume a T lymphoid differentiation identity, 
whereas while OP9 cells bearing Jagged1 or Dll3 do not. However, in a fucose-deficient 
experimental situation, FX(-/-) bone marrow cells fail to assume a T lineage identity when 
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co-cultured with OP9-Dll1, OP9-Dll4 or OP9-Jagged2, and fail to initiate Notch1 signaling 
events. These results indicate that fucosylation is required for Notch1 signaling-dependent 
T cell differentiation. 
 
Introduction 
Precisely correlating a phenotype with a specific cellular event in knockout mice is 
sometimes difficult due to factors such as the multiple functions of a protein, systematic 
defects, the crosstalk of signaling pathways, and environmental effects. In our study of FX(-
/-) mice, it is even more difficult, since fucose is integrated into all different kinds of glycan 
structures.  Fucosylated glycans can be found on a tremendous number of cell surfaces and 
intracellular proteins. Thus it is almost impossible to determine which exact fucosylated 
protein contributes to the thymic atrophy of FX(-/-) mice off fucose. However, similar 
thymic atrophy phenotypes can be found in other mouse models, which could hint at ways 
to narrow down the possibilities. In Chapter II, all of the proposed T cell progenitors in 
FX(-/-) hypoplastic thymus were enumerated, and the cell distribution patterns were 
compared.  
 
Disruption of the Notch Signaling Pathway Results in Mature Thymocyte 
Loss 
The FX(-/-) off-fucose thymus contains very few CD4+CD8a+ DP cells, a decrease 
of about 1000 fold compared with the wild-type thymus. DP cell loss has also been 
reported in a few strains of genetically engineered mice. Notch1 conditional knockout mice 
have partially suppressed Notch1 gene expression in the thymus, and 90% of thymocytes 
were lost in the thymus of these mice (77). DP and SP populations were 3 to 5 fold 
decreased in cell numbers in Notch1 conditional knockout mice. Since Notch1 conditional 
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knockout mice still had 75% of the Notch1 gene expression left in the thymus, the greater 
cell loss was expected if the Notch1 gene was completely suppressed. The second mouse 
model was the conditional knockout mouse of RBP-J, which encodes a Notch1 downstream 
signaling partner. This mouse displayed a 90% total cell loss 3 months after being induced 
and an approximately 10 fold of reduction of DP and SP T cells (198). RBP-J conditional 
knockout mice had a 25% RBP-J gene expression left in the thymus and were also expected 
to have a more severe phenotype in a complete knockout condition. The above results 
strongly indicate that disruption of Notch1 signaling immediately results in a loss of mature 
thymocytes.  
 
Disruption of Notch Signaling Accounts for the Decrease of ETPs 
Secondly, early thymic progenitors were missing in the FX(-/-) thymus off fucose 
for 4 weeks. In Chapter II, the DN1a-b population of the FX(-/-) hypoplastic thymus was 
greatly reduced, while some enrichment of DN1e population was observed. This pattern is 
very similar that in another study, in which the thymic progenitors lacked Notch1 signaling 
(162). Transduction of DNMAML1, a dominant negative regulator that inhibits Notch1 
downstream signaling into bone marrow progenitors, resulted in the reduction of DN1a-b 
population within early T cell progenitors, with a slight accumulation of DN1e population. 
This DN1a-e distribution pattern is very similar to that of the FX(-/-) off-fucose thymocytes 
and strongly suggests a probable interruption of Notch1 downstream signaling in FX(-/-) 
mice. 
In summary, comparing with the mice or the cells that lack of Notch 1 signaling, the 
FX(-/-) thymic atrophy has the similar defect during T lineage commitment. The hypoplastic 
thymus of FX(-/-) mice is very likely due to a similar disruption of Notch1 signaling.  
 
O-fucosylation is essential for Notch1 Signaling 
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Within the components of Notch1 signaling, Notch receptors and Notch ligands are 
subjected to fucosylation on the EGF domains (15, 199). Fucose was known found as the 
terminal differentiation for glycan structures, but recently found also in an O-linked fashion. 
The O-fucose glycans are found at Serine/Threonine residues of consensus sequence 
C2XXGGS/TC3 within the second and the third cysteine of the EGF repeats (56). The 
enzyme responsible for adding fucose to the EGF repeats was first cloned in hamsters (16), 
then in humans and mice (17), and later in Drosophila (25). This enzyme was designated 
with the name of protein O-fucosyltransferase 1 (POFUT1).  
Biochemical experiments have proved the important roles of fucosylation to Notch 
downstream signaling in Drosophila and mammalian systems. By using RNA interference, 
knock down of OFUT1 in Drosophila results in a notched wing phenotype resembling that 
of Notch null mutants (25). The Notch downstream target gene expression was regulated by 
POFUT1. In another study, the disruption of O-fucosyltransferase 1 gene in Drosophila, 
also known as Neurotic, resulted in a wing-notched phenotype similar to Notch mutants 
(200). These two independent studies indicated the requirement of POFUT1 in Notch 
signaling. Furthermore, the GMD mutant Drosophila has a global fucosylation deficiency 
in theory and displays a wing development defect similar to Notch mutant flies (201). In the 
mammalian system, O-fucosyltransferase 1 knockout mice display a embryonic lethal 
phenotype (58) that resembles Notch1 knockout mice (77), indicating defects in signaling 
pathways related to development. These observations suggest an essential role of O-
fucosylation in the Notch1 signaling pathway.  
In this chapter, we hypothesized that the FX(-/-) thymic atrophy phenotype was due 
to a lack of O-fucosylation and resulted from a Notch1 signaling deficiency. We first 
reconstituted Notch1 signaling in vivo and in vitro and tested whether Notch1 signaling was 
sufficient to rescue T lymphocyte development. Further, Notch1 downstream signal targets 
and the T cell specific transcription factor gene were studied with regard to the function of 
fucosylation. Our results indicate that Notch1 signaling is regulated by the function of 
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fucosylation in FX(-/-) hematopoietic progenitors and that fucosylation is required for T 
lymphocyte development.  
 
Methods 
Materials- All experiments were conducted in accordance with National Institutes of 
Health guidelines for the care and use of animals and with an approved animal protocol 
form the University of Michigan and Case Western Reserve University Animal Care and 
Use Committees. C57B/6 mice were obtained from Jackson laboratory. FX knockout mice 
were made by as previously described(93). FUT4/7 double knockout mice (DKO) were 
made, again as previously described (53).  
Total thymocytes isolation-The thymus was isolated from the mice and mechanically 
disrupted to make a single cell suspension. Thymocytes were first resuspended in red blood 
cell lysis buffer (Sigma) at room temperature for 5 minutes, and washed twice in Hank’s 
Balanced Salt Solution (HBSS, Gibco) with 0.1% Bovine Serum Albumin (BSA, Sigma). 
Cells were collected by centrifugation and resuspended for cell counts by Trypan blue  
Bone marrow isolation- Bone marrow cells were flushed out in HBSS with 0.1% 
Bovine Serum Albumin (Tissue culture tested, Sigma) from the femur and tibia of the mice. 
Red blood cells were lysed after isolation with red cell lysis buffer (Sigma). Lineage 
depletion was carried out by incubating the cells with biotinylated anti-mouse CD3, CD4, 
CD8a, %#TCR, B220, Gr-1, CD11b, Ter-119, NK1.1  (BD, Pharmingen) antibodies 
followed by magnetic bead depletion (Miltenyi Biotec). Lineage depleted cells were used for 
retrovirus transduction. For LSK isolation, the lineage-depleted cells were further stained 
with FITC-anti-mouse Sca-1 and APC anti-mouse c-Kit antibodies.  
As one alternative method, 5’-Fluorouracil treatment was used to deplete mature 
bone marrow cells, as previously described (202). In brief, 5’-Fluorouracil was 
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intraperitoneally injected with 150mg/kg to each mouse. Five days after injection, treated 
bone marrow cells were isolated and used directly as donors.  
Retrovirus- Notch 1 intracellular domain (ICN1) (1735-2531) was inserted into 
pMIG vector to form pMIG-Noch1IC-EGFP, which was subsequently transfected into 
Phoenix E packaging cells. Viral supernatant was collected 2 days after the transfection and 
kept frozen at -80°C. The titer of retrovirus was determined by transduction to NIH3T3 
cells in a serial dilution assay (data not shown). The transduction efficiency to NIH3T3 was 
above 90% on average (data not shown). 
Retroviral transduction- ICN1 retrovirus was transduced as previously described 
(202). In detail, the isolated bone marrow progenitors were plated in 6 well plates in IMDM 
(Gibco) with 10%FCS (Hyclone), 1xL-glutamine (Gibco), 1xPrecillin/straptmycin (Gibco), 
6ng/ml IL-3, 10ng/ml IL-6, and 100ng/ML Stem Cell Factor (R&D system). On the second 
day, the cells were centrifuged down in the plates at room temperature for 5 minutes at 
1300rpm. Undiluted retrovirus supernatant was added to each well for maximum 
transduction efficiency. Polybrene was added to each well at the final concentration of 
4ug/ml. The virus cell mixture was sealed in the dish and centrifuged at room temperature 
for 2 hours at 900g (2500rmp of table top centrifuge). Right after transduction the IMDM 
medium was changed and fresh IMDM medium was added to the cells. On the third day, 
the cells were again transduced with the same procedure and again cultured overnight.  
Intrathymic injection- Donor cells were analyzed by flow cytometry prior to 
injection. For each recipient, 5x105 donor cells were injected intrathymically after being 
reared off fucose for 6 days. On day 17, the thymus of recipients was isolated and the 
thymocytes were analyzed. 
OP9 co-culture- OP9 stromal cells (ATCC) were transduced with bicistronic Ret10-
EGFP vector alone or with a different full length Notch ligand inserted. Different OP9 cell 
lines were sorted with the same EGFP expression level to ensure the same expression level 
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of transduced genes. The function of different Notch ligands on OP9 has been tested by co-
culture OP9 cell lines with C2C12 myoblasts as previously described (203).  
1000 LSK cells were cultured on different OP9 cell lines with 1ng/ml of IL-7 and 
5ng/ml of Flt3 ligand (carrier free, R&D system), as previously described (204). The 
culture was disrupted by vigorously pipetting on day 8 and day 12. One fifth of each well 
was transferred to the newly plated OP9 cells in each passage with new cytokines added in 
each passage. Analysis of the culture was performed on day 20. 
5x104 to 1x105 total thymocytes (equivalent to one FX/- off-fucose thymus) were 
cultured on different OP9 cell lines with 1ng/ml of IL-7 and 5ng/ml of Flt3 ligand (carrier 
free, R&D system), as previously described (204). On day 8, the co-culture was disrupted 
by vigorously pipetting, and all of the cells were passed to new layers of OP9 cells, with 
fresh cytokines added. On day 13, half of the disrupted culture was kept for analysis, while 
the other half of the culture was transferred onto new OP9 layers. The remaining culture 
was analyzed on day 20.  
Real-time quantitative PCR- LSK cells cultured on OP9 cells were sorted via flow 
cytometry after 8 days in different OP9 co-cultures. The LSK progeny was gated by the 
right lymphoid-like size in the side and forward scatter gate, together with the GFP negative 
gate. Post-sorting efficiency was examined to ensure that the purity of LSK progeny was 
over 98%. RNA was isolated by using RNeasy plus (Qiagen) and then reversely transcribed 
by iScript kit (Bio-Rad). cDNA amplification was carried out using SYBR green Supermix 
reagents (Bio-Rad) on iCycler (Bio-Rad).  
Primers--Primers were designed by MacVector software and the products of 
amplification were ensured within 100-150bp. Primer efficiencies were tested prior to the 
experiments by the serial dilution of the total thymocyte cDNA samples (data not shown). 
The primer pairs used had a typical efficiency of around 2.0 by experiment and in theory. 
GAPDH (forward: TCAAGAAGGTGGTGAAGCAGGC, backward: 
AAGGTGGAAGAGTGGGAGTTGC), Hes-1 (Forward: 
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AAATGACTGTGAAGCACCTCCG, Backward: TCACACGTGGACAGGAAGC), 
Deltex-1 (Forward: AAAGCGACGTGAAGCCTGTGC, Backward: 
TCACCTTCTGCATGTACCTCCG ), GATA-3 (Forward: 
TCTGGAGGAGGAACGCTAATGG, Backward: TTTCGGGTCTGGATGCCTTC).  
 
Results 
Notch1 Signaling Rescues the Defect of T cell Development in FX(-/-) Mice 
off Fucose In Vivo.  
To determine the mechanism for the thymic atrophy in FX(-/-) mice reared in a 
fucosylation-deficient state, we first asked if similar phenotypes had been reported in other 
genetically engineered mouse models. The majority of the thymocytes lost in the absence of 
fucosylation are due to the sizable decease of CD4+CD8a+ mature T cells as well as 
downstream single positive populations. The loss of mature T cell populations has been 
observed in several mouse models, including NOD/LtSz-scid mice (205), IL-7 Receptor -/- 
mice (206), Rag1-/- mice (207), and notably, inducible Notch1 knockout mice (77). Notch1 
knockout mice had a dramatic decrease of DP cells and SP cells. More excitingly, Notch1 
proteins are fucosylated, while IL-7 receptor and Rag1 proteins have not been reported as 
fucosylated glyco-conjugates. Thus, losing fucosylation does not likely disturb the 
functions of the IL-7 receptor and Rag1 recombinase. Rather, these observations indicate 
that the loss of T differentiation potential in FX(-/-) progenitors was very likely due to 
abolishing the functions of Notch1 receptors on the cell surface.  
In the absence of fucosylation, FX(-/-) mice lost multiple T cell progenitor 
populations, including the early T cell progenitors (ETPs) defined by CD117+CD24-IL7R-
"- within DN1 cells. The ETPs are generated in a Notch-dependent manner (162). Loss of 
the ETPs has also been observed in the thymic progenitors where Notch1 signaling was 
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suppressed by DNMAML1 (162). These observations pointed to a Notch1 signaling 
deficiency in non-fucosylated T cell progenitors as a mechanism that accounts for thymic 
atrophy in the FX(-/-) mice.  
To determine whether Notch signaling can rescue T cell differentiation in FX(-/-) 
mice off fucose for 4 weeks, Notch1 signaling was introduced by retroviral transduction of 
the Notch1 intracellular domain (ICN1) in bone marrow progenitors, as previously 
described (202). ICN1 was inserted into the bicistronic retroviral vector pMIG that has an 
internal ribosome entry site (IRES). IRES on pMIG allows the inserted gene (ICN1) to be 
independently expressed with an Enhanced Green Fluorescence Protein (EGFP) cassette. 
Thus the ICN1 gene expression may be monitored by the EGFP expression in the same 
cell. The pMIG-ICN construct was transfected into packaging cells, Phoenix E, and the viral 
containing medium was then collected for the transduction (208). Virus viability has been 
tested by transduction to NIH3T3 fibroblast cells with a typical >95% efficiency.  
Donor bone marrow progenitors (CD45.1) from FX(-/-) mice off fucose for 4 
weeks were enriched via two different methods. First, 5-fluorouracil was used for injection 
to the animal in vivo in order to deplete mature bone marrow cells. In the second method, 
lineage depletion via magnetic beads was carried out on untreated total bone marrow cells ex 
vivo. Since not every single donor cell was transduced, cells expressing ICN1 were traced 
by EGFP expression and CD45.1 expression. Lineage analysis was carried out before 
injection. No CD4 and CD8a expression were detected after transduction in the progenitor 
cells (data not shown).  
To bypass the possible homing deficiency of FX null cells, 5x105 transduced bone 
marrow progenitors in 10µl of PBS with 1% BSA were injected intrathymically into the 
FX(-/-) (CD45.2+) recipient mice off fucose for 6 days, when the thymus was big enough 
for the injection. As shown in Figure 3-1, three populations were injected separately in each 
experiment. The viral vector transduced bone marrow donors from wild-type mice were 
used as positive controls. The viral-vector-transduced donor FX(-/-) off-fucose cells were 
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used as negative controls. The experimental group was the ICN1 transduced FX(-/-) off-
fucose progenitor cells. The recipient thymus was analyzed 17 days post-transplantation by 
flow cytometry, in accordance with the previous studies (165). 
Figure 3-2 show one representative flow data out of 10 experiments on day 17 post-
injection. Transduced donor cells were gated by CD45.1 positive expression and GFP 
positive expression. The left-panel shows that the wild-type bone marrow progenitors 
transduced with the pMIG vector were capable of differentiating into CD4+CD8a+ mature T 
cells in the FX(-/-) recipient thymus. The FX(-/-) bone marrow progenitors transduced with 
the pMIG vector remained in the CD4-CD8a- stage (middle panel) and were not able to 
differentiate into mature T cells. However, when ICN1 was expressed in the FX(-/-) bone 
marrow progenitors,  these progenitor cells were able to differentiate into CD4+CD8a+ T 
cells (right panel). These observations indicate that the in vivo restoration of Notch1 
signaling rescued the ability of FX(-/-) bone marrow progenitors along the T lineage 
developmental pathway in the fucose-deficient environment. These results suggest that the 
hematopoietic progenitors of FX(-/-) mice were deficient regarding Notch1 signaling.  
 
Fucose-dependent Notch1 Signaling Rescues FX(-/-) off Fucose in T Cell 
Development In Vitro 
To further confirm that restoring Notch1 signaling in non-fucosylated FX(-/-) T cell 
progenitors can fully recover mature T cell generation, an in vitro assay for T cell 
differentiation was used, including the co-culture system with OP9 stromal cells (209). As 
has been shown in recent studies, the generation of CD4+CD8+ T lymphocytes from the 
different multi-potent progenitors can be achieved by using Dll1 transduced OP9 cells (159, 
204, 210, 211). In our study, each of the five mammalian Notch ligands was tested to define 
their specific functions in the T cell development pathway. 
The OP9 cells from ATCC were transduced with different constructs in Ret10 
bicistronic EGFP-containing retroviral vector (as shown in Figure 3-1). Each construct 
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contained one of the five full-length Notch ligand mouse cDNAs (Dll1, Dll3, Dll4, Jagged-
1, or Jagged-2). The control OP9 cell line was transduced with an “empty” Ret10 vector. 
Transduction efficiency was examined by the EGFP protein expression. All six transduced 
OP9 cell lines were sorted for the same medium/low EGFP expression level (data not 
shown). Further, these OP9 cell lines were tested in the C2C12 myotube differentiation 
assay to test the functionality of each ligand (Stephanie Chervin and John Lowe, 
unpublished data). Each of the OP9-ligand cell lines, except the OP9-Dll3, have inhibitory 
effects on the myotube differentiation (data not shown), as previously reported (212, 213).  
The LSK (Lineage- c-Kit+ Sca-1+) cells sorted from 12-week-old wild-type mice 
were first used to characterize this co-culture assay. Post-sort analysis was carried out to 
ensure purity (90% in average). On day 0 of the culture, 1000 LSK cells from wild-type 
mice were seeded on OP9 cell lines (204, 210, 214) in the presence or absence of 1mM 
fucose. A IL-7 concentration lower than 5ng/ml of the original reported system was used to 
optimize T cell generation (210). Since our purpose was to provide the in vitro assay that 
favors T cell development, 1ng/nl IL-7 was consistently used, as in the previous report 
(210).  
On OP9 cells transduced with Ret10 or with Ret10-Dll3 or with Ret10-Jagged-1, 
wild-type LSK differentiated along the B lineage and myeloid lineages in the presence and 
absence of fucose, which confirmed previous reports that B and myeloid lineage 
differentiation proceeds in the absence of Notch1 signals in some circumstances (204, 214). 
Dll3 and Jagged-1 were designated as “non-functional ligands” for T cell development. 
However, B cell generation in OP9-Dll3, OP9-Jagged1 or control OP9 culture in WT and 
FX(-/-) LSK has occurred with differing incidence among experiments, and even among the 
wells in the same experiment, which indicates that the culture condition was not optimized 
for B cell development, as previously seen (162). In contrast to the B cells, myeloid cells 
were consistently generated, indicating that myeloid lineage is the default pathway in the 
absence of Notch1 signaling. 
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Among all the culture conditions, OP9 cells expressing Dll1, Dll4 or Jagged2 
supported the generation of CD4+CD8a+ T cells from the wild-type bone marrow LSKs 
(Figure 3-3) in the absence and presence of fucose. We designated Dll1, Dll4 and Jagged2 
as “functional ligands” for T cell development. Among those ligands, Dll4 and Jagged2 
containing cultures generated 6-8 times more T cells percentage-wise, indicating that Dll4 
and Jagged2 are more efficient than Dll1 in conferring T cell differentiation in this assay. 
The cell proliferation abilities, shown as number per input cells, were consistent with this 
observation (Figure 3-5). More interestingly, our results corresponded to the observations 
that Dll4 and Jagged2, but not Dll1, were greatly expressed in the thymus (215). These 
observations suggest that multiple Notch ligands play redundant roles in T cell generation 
while displaying different abilities. These results also imply a more complicated and finely 
regulated system in mammalian hematopoietic developmental pathways.  
As shown in Figure 3-4, FX(-/-) off-fucose LSK did not progress to mature 
CD4+CD8a+ T cells in the absence of Notch ligands, or when non-functional Notch 
ligands were present (OP9, OP9-Dll3, OP9-Jagged1) in culture. These FX(-/-) cells derived 
to B cell or myeloid lineage cells regardless of the fucose present in culture, indicating that 
fucosylation is dispensable in B and myeloid lineage decisions. In the absence of fucose, 
even in the functional-ligand containing cultures (OP9-Dll1, OP9-Dll4, or OP9-Jagged2) 
myeloid and B cell were generated with full suppression of T cell development. Only when 
1mM fucose was added to the culture was the T cell development pathway restored in FX(-
/-) off-fucose bone marrow progenitors. These results indicate that T cell development is 
fucosylation-dependent only in the presence of “functional Notch ligand”. These 
observations also suggest that the function of Notch1 signaling in T lineage commitment is 
fucosylation-dependent. 
 
Fucosylation Controlled Notch1 Signaling Is Required for Intrathymic 
Development.  
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T progenitors developed from stem cells in bone marrow and travel via the blood to 
the thymus, where they further mature. The precise steps along this differentiation pathway 
are not yet fully understood (216-219). Although T cell development may be rescued in vivo 
and in vitro by restoring Notch1 signaling to FX(-/-) off-fucose bone marrow hematopoietic 
progenitors as shown in the previous experiments, it was not known if there were “blocks” 
inside the thymus along T differentiation.  
Phenotypic analysis in Chapter II indicated that the multiple-potent T cell 
progenitors were lost from the thymus of FX(-/-) mice off fucose for 4 weeks (Figure 2-5, 
2-6, 2-7). The paucity of the remaining cells within each T progenitor population makes it 
extremely difficult to complete biochemical or functional assays with these cells. To 
determine whether fucose is required for intrathymic progenitor development, total 
thymocytes from FX(-/-) mice off fucose 4 weeks were isolated and co-cultured with the 
OP9 and OP9-Notch ligand expressing cells in the presence or absence of 1mM fucose. 
Although multiple potential T progenitors were used in the same culture system, the 
proliferation potential of cells in OP9 culture would easily help us to find out if progenitors 
were blocked from maturation along the differentiation pathway.  
For each experiment, the thymuses from 39 FX(-/-) mice reared off fucose for 4 
weeks was isolated and the thymocytes were isolated by mechanic disruption. The 
thymocytes were combined in 3 different groups. In each group, 1/13 of the cells were 
phenotypically examined by flow cytometry to ensure that no DP cells were seeded in the 
culture (Figure 3-6 day 0). Then each group of cells was equally divided and seeded in 12 
different wells (6 different OP9 cell lines with 2 conditions with or without fucose). Thus in 
each culture condition, 3 different wells were seeded in parallel. For each group of the cells, 
a fair comparison could be made within all 6 different conditions. 
 On average, 5x104 to 1x105 cells (equivalent to one FX(-/-) thymus off fucose 4 
weeks) were seeded in the wells of a 24-well plate. With a supplement of fucose in the 
medium, thymocytes proliferated over time in OP9-Dll1, OP9-Dll4 or OP9-Jagged2 
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cultures (Figure 3-7a). Lineage commitment to CD4+CD8a+ cells was observed by flow 
cytometry on day 13 (Figure 3-6) and day 20 (data not shown) in OP9-Dll1, OP9-Dll4 and 
OP9-Jagged2 cultures. These observations are consistent with OP9 cultured with FX(-/-) 
off-fucose LSK cells (Figure 3-4). However, in the absence of fucose, the thymocytes did 
not proliferate and in fact disappeared over time, in OP9-Dll1, OP9-Dll4 and OP9-Jagged2 
cultures (Figure 3-6a). Proliferation and differentiation along myeloid (CD11b+Gr1+) and B 
(B220+CD19+) lineages was not observed in these culture conditions (data not shown).  
The FX(-/-) thymocytes also disappeared over time on OP9-Ret10, OP9-Dll3 and 
OP9-Jagged1 cultures regardless of fucosylation, indicating that Notch1 signaling is 
required for intrathymic development. Proliferation and differentiation along myeloid 
(CD11b+Gr1+) and B (B220+CD19+) lineages was not observed in these culture conditions.  
Several potential populations in the FX(-/-) off-fucose total thymocytes have the 
potential to progress through DP cells, including Lin-DN1, Lin-DN4 and DN1e (159, 214). 
Although we could not pinpoint the exact populations giving rise to DP cells, these 
observations indicated that, in one or more developmental transition, within the thymus 
fucose is required for Notch1 signaling related to T cell generation.  
 
Fucosylation Dependent Notch1 Downstream Target Gene Expression and 
Lineage Related Gene Expression 
Fucosylation is required for Notch1 downstream signaling in many different in vitro 
and in vivo systems, including the wing development of Drosophila (25, 58). However, the 
role of fucosylation in the Notch1 downstream signaling along T cell differentiation of 
mammals has not yet been examined. To directly confirm our previous observations, we 
further examined the activation of Notch downstream targets together with lymphocyte 
lineage related genes in the presence and absence of fucose in the LSK and OP9 cells co-
culture system. 
 71 
After 8 days in culture, 10,000 LSK progeny were sorted directly into lysis buffer 
by lymphoid-like light scatters and GFP negative, which eliminated contamination by OP9 
cell lines that are GFP positive and have higher light scatters. Real-time PCR with 
SYBRGreen dye was used to monitor the expression levels of different genes. To further 
normalize the cell number, GAPDH was used as the internal reference.  
Two Notch1 downstream targets were tested, Hes-1 (220, 221) representing RBP-J 
dependent signaling target, and Deltex-1(222, 223) as a RBP-J independent signaling target. 
In OP9-Dll3, OP9-Jagged1 and OP9 culture, Hes-1 and Deltex-1 were not activated in the 
cultures, regardless of the presence or absence of 1mM fucose. In OP9-Dll1, OP9-Dll4, 
and OP9-Jagged2 cultures, Hes-1 mRNA expression were upregulated 25 times or more in 
the presence of fucose (Figure 3-8), while Deltex-1 mRNA was increased in its expression 
more than 300-fold (Figure 3-8).  
Pre T-alpha is a Notch1 downstream target (224) and is expressed on DN3  
populations (224-226), specifically along T cell development. However, pT-alpha mRNA 
transcripts were so few to be detected in those LSK progenies (data not shown). GATA-3 is 
so far the specific transcription factor for T lineage (227) and was used in the same 
experiments to monitor the T lineage potential of cells. Similar to Hes-1 and Deltex-1, 
GATA-3 was expressed fucosylation-dependently in the FX(-/-) progenitor cells in Dll1, 
Dll4, and Jagged2 containing OP9 co-cultures (Figure 3-8). Although other fucose-
dependent signaling pathways may contribute to T cell development, our observations 
strongly indicate that fucose is required for the activation of Notch1 downstream signaling 
as well as the T cell differentiation. The correlation of fucose-dependent Notch1 
downstream signaling activation and fucose-dependent T cell differentiation has shown that 
in the absence of fucose, the LSK progeny displayed the silence of Notch1 downstream 
activation and they were unable to differentiate to T cells. These results also imply that the 
pathogenesis of the FX(-/-) thymic atrophy is the disruption of Notch1 downstream 




FX(-/-) mice have a fucosylation-dependent hypoplastic thymus. Analysis of 
thymocyte populations in these mice pointed out a developmental defect of T cells that 
correlated with a loss of fucosylation. Early T cell progenitors are missing in the atrophic 
thymus, due to the loss of fucosylation. These conclusions from Chapter II raised the 
question of how fucosylation controls T lymphocyte differentiation. In comparison with the 
phenotypes of other experimental models, it was proposed that fucosylation ceases T cell 
development by disrupting Notch1 signaling. The experiments outlined in Chapter III were 
designed to test this hypothesis. Our observations in Chapter III reveal an important role for 
fucose in Notch1 signaling in the T cell differentiation pathway.  
First, we took the approach of reconstituting Notch1 signaling in vivo by 
transducing the intracellular domain of Notch1 into hematopoietic progenitors. Retroviral 
transduction has been widely used to introduce genes to cells that are difficult to transfect. 
Bone marrow stem cells are difficult to transfect, and the efficiency of retroviral transduction 
is relatively low. Several studies indicate that only 0.1% to 1% of the human pluripotent 
hematopoietic stem cells are potentially targeted during retroviral transduction (228, 229). In 
murine models, retrovirus has been widely used and nearly every experimental detail of 
designing retroviral vector to increase transduction efficiency has been greatly improved 
over time. The Phoenix E packaging cell line (230) was made based on the genetically 
engineered BOSC 23 cell line capable of producing high-titer helper-free retrovirus (231). 
Compared with the BOSC 23 cell line, the Phoenix E (Phoenix Ecotropic) cell line is highly 
transfectable with either calcium phosphate mediated transfection or lipid-based transfection 
protocols. High-titer retroviruses were obtained in 3 days by transient transfection in 
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Phoenix E cells. Thus highly active retroviruses were used in transduction in order to 
increase the transduction efficiency.  
Notch1 intracellular domain inserted retrovirus has been used previously to identify 
the functions of Notch signaling in various experimental systems. Warren Pear and 
colleagues have defined the transduction protocol in their studies of Notch1 signaling in T 
cell leukemia (76, 202, 232-234). Spinoculation during transduction was applied in our 
procedure so that the maximum amount of virus could hit bone marrow stem cells (235). In 
addition, retroviral transduction on the same stem cell population twice in consecutive days 
potentially increased the ratio of transduced cells (232).  
The intrathymic injection technique was developed to study the process of bone 
marrow cell homing to the thymus. This is a complicated surgical procedure made even 
more challenging by the small size of the FX(-/-) recipients with a hypoplastic thymus. 
Transduced cells were analyzed carefully right before being injected into the recipient mice. 
EGFP expression has been seen in transduced bone marrow cells to validate the 
transduction. Cell surface markers of CD4 and CD8a were used in the analysis of 
transduced bone marrow progenitors in order to ensure the early developmental stage of 
injected cells. No mature T cell populations were identified in the transduced bone marrow 
cells that were injected. This observation has been consistent across our 10 or more 
experiments.  
The functions of Notch1 and its ligands in hematopoietic cell differentiation have 
long been sought in different in vitro experimental setups. Soluble human Dll-1 was shown 
to delay the differentiation of mouse hematopoietic progenitors in a culture dish (236). 
Meanwhile, hDll-1 promoted the expansion of primitive precursors in vitro. Plated-coated 
Notch ligand of Dll1 was shown to be required for Notch signaling and downstream gene 
activation (203). However, bone marrow cells cultured on plate-bound Dll1 could only 
progress to the DN2 (CD25+) stage along T cell development. To identify the role of 
Notch ligands in lymphoid differentiation pathways, L. Parreira and colleagues expanded 
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the idea from a co-culture system (237), in which bone marrow stem cells were cultured 
with a bone marrow stromal cell line. In their studies, bone marrow stromal S17 cell line 
was transduced with different Notch ligands and was coated as the bottom layer in co-
culture with human bone marrow progenitors (238). Our initial adaptation of this co-culture 
system by Lan Zhou and Stephanie Chervin for the study of T cell differentiation was not 
able to identify the generation of mature T cells (unpublished data). However, it seems that 
greater T cell differentiation efficiency is achieved with another bone marrow stromal cell 
line of OP9 (204). It is not yet known how S17 cells differ from OP9 cells in terms of 
conferring T cell differentiation in vitro. 
Originated from OP9-Dll1 co-culture system by Juan Carlos Zúñiga-Pflücker and 
colleagues (239), OP9 cells have been widely used in co-culture experiments in order to 
identify the roles of different Notch ligands. OP9-Dll1 cells have been shown to support T 
lymphopoiesis from mouse fetal liver cells (204) or adult bone marrow stem cells and 
embryonic stem cells (211). Progenitors from fetal liver were consistently able to progress 
to mature T cells on OP9-Dll1 (204, 240). However, the generation of CD4+CD8a+ T cells 
from bone marrow hematopoietic stem cells was not as reproducible on OP9-Dll1 cells 
(210). In our study, Dll1 had the weakest ability to induce T cell differentiation compared to 
Dll4 and Jagged2, which has not been reported in previous literature. Dll1 was recently not 
extensively expressed in the thymus, while Dll4 and Jagged2 were identified with a much 
higher expression level (215), indicating that Dll4 and Jagged2, but not Dll1, may actually 
play roles in thymocyte development. This result confirmed our observations of different 
functional abilities within Notch ligands that are able to induce T cell differentiation. 
Further, by comparing culturing systems of OP9-Dll1 and OP9-Dll4 (241), a recently 
published observation indicated that Dll4 has stronger abilities during T cell differentiation 
in vitro, which in part confirms our results.  
Moreover, previously only Jagged1 and Dll1 among all five Notch ligands have 
been extensively compared, in terms of functional roles (214, 238). Our work, again for the 
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first time, compared all Notch ligands in their functions of T cell differentiation in parallel. It 
is very interesting that Jagged1 and Jagged2 showed distinct functions during T cell 
development though in protein sequences they very closely resemble each other. It is not yet 
known how Jagged1 and Jagged2 transduce different Notch downstream signals. It is also 
intriguing that Jagged2 and Dll4 functionally resemble each other and yet possess very 
distinct protein sequences.  
Mammalian cells possess five different Notch ligands, while flies have only two 
homologues. It is important to understand the differences among those ligands in order to 
understand the regulatory system of mammals in Notch signaling. By providing the 
functional information, our results potentially initiate the future study of Notch ligands with 
regard to their structures and signaling mechanisms.  
Notch downstream signaling is very complicated in the way that many downstream 
targets are transcription factors themselves. These transcription factors such as Hes-1, 
Deltex-1 may activate many other genes, which forms complex signaling cascades. 
However, in order to induce Notch signaling, a simple process is required, namely the 
release of the Notch intracellular domain. In a biological context, Notch ligands interact with 
Notch receptors and induce a conformational change of the receptors, thus Notch receptors 
are processed by ADAM protease and gamma-secretase sequentially. There are many 
mechanisms potentially regulating the Notch signaling pathway, and our results have shown 
one possibility of fucosylation-dependent regulation. In the absence of fucosylation, Notch 
downstream genes are silenced and the T cell specific transcription factor (GATA-3) was 
not expressed. When Notch receptors are fucosylated, Notch signaling was transduced and 
downstream genes were expressed. The level of the fucosyltransferases expressed tightly 
regulates the presence of fucosylated structures. Recently, missing certain fucosylated 
glycans on Notch1 receptors was shown to interfere Notch1 downstream signaling (242). 
Our results and others suggest a mechanism by which regulating the expression of O-
fucosyltransferase 1 may control the downstream gene expression of Notch1 signaling in T 
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cell progenitors in order to sustain the normal amount of mature T cells produced within 
mammals. This result suggests a novel function of fucosylation in the cellular regulatory 
system of mammalian development. 
The results in Chapter III raise another question: how fucosylation regulates Notch1 
signaling. Based on the conclusions introduced in the previous chapters, Chapter IV focuses 
on our approach to this question.  
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Notes to Chapter III 
1Acknowledgments: We thank Peter Smith for technical support on intrathymic 
injection, Lan Zhou for initialization of OP9 culture, Stephanie Chervin and Melissa 
Ruffs for transducing OP9 Notch ligand bearing cell lines, Kary Oetjen for effort 
on setup real time PCR, Ying Plews and Rocio Guardia-Wolff for genotyping mice, 
and R. Michael Sramkoski at Case Western Reserve University Cancer Center 
Cytometry Core Facility for technical advice on cell sorting. 
  
2Attribution of data: Melissa Ruffs and Bronia Petryniak cloned all of the DNA 
constructs used. Bronia Petryniak performed the transduction and contributed to 
intrathymic injection in Figure 3-1. Jay Myers performed the thymus dissection 
depicted in Figure 3-1. Clare Rodgers performed most of the FACS analysis in 
































Figure 3-1: Experimental designs of intrathymic 
injection. a. Illustration of DNA constructs used in producing 
retrovirus. b. Experimental scheme. Bone marrow progenitors 
were differently transduced and intrathymically injected into 
FX(-/-) off fucose recipient. 17 days after the injection, thymus 

































Figure 3-2: Notch1IC rescues FX(-/-) thymic atrophy in 
vivo. Transduced cells were identified by EGFP expression 
during analysis 17 days post injection. b. Representative of 10 
















Figure 3-3: WT LSK co-cultured with OP9 cell lines. 
Representative of 6 and more experiments, in which WT bone 
marrow LSKs were cultured on different OP9 cell lines as 



















Figure 3-4: FX(-/-) off fucose LSK co-cultured with OP9 
cell lines. Representative of 6 and more experiments, in which 
FX(-/-) off fucose 4 weeks bone marrow LSKs were cultured 
on different OP9 cell lines as indicated for 20 days, in the 



















Figure 3-5: Cell proliferation in OP9 cultures. Left panels 
show the number of different cells per input as day 0 from FX(-
/-) OP9 coculture (Figure 3-4) comparing with the ones in right 
panels from WT OP9 culture (Figure 3-3). Bar graphs 
represent the average of 10 or more data in 6 experiments, with 




Figure 3-6. Fucosylation controlled Notch1 signaling is 
required for intrathymic development. Total thymocytes 
from FX(-/-) off fucose for 4 weeks were flowed at day 0 and 
seeded on different OP9 Notch ligand-bearing cells. After 13 
days, cells were collected and analyzed by flow cytometry. Here 







Figure 3-7 Cell proliferation of total thymocyte in OP9 
cultures. a. Total cell proliferation upon the time has been 
shown in different OP9 cultures. b. CD4+CD8a+ DP cells 





Figure 3-8: Notch1 downstream gene expressions of LSK 
progenies on day 8 in OP9 co-cultures. One of 3 
independent experiments shown here with the mRNA 
expression monitored by real-time PCR. Hes-1 (top), Deltex-1 
(middle) and GATA-3 (bottom) expression detected in 10, 000 
LSK progenies sorted after cultured with OP9 cells for 8 days.  
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Chapter IV 
Molecular regulations of Notch1 signaling by 
fucosylation 
Abstract 
Fucosylated glycans contribute to important cellular events, including the 
modulation of the Notch1 intracellular signaling pathway by modifying the epidermal 
growth factor (EGF) like repeats. Previous evidence suggests that a loss of fucosylation on 
Notch1 abolishes its signaling ability and its functions in T cell differentiation. To define 
the molecular mechanisms that account for fucosylation-controlled Notch1 signaling 
activation, I completed experiments to ask 1) whether fucosylation controls the amount of 
cell surface Notch1 expressed by cells, and 2) whether fucosylation modulates the strength 
of the interaction between Notch1 and its ligands. These experiments allowed me to 
conclude that (1) fucosylation controls the strength of binding between Notch1 and its 
ligand Dll4, using OP9-Dll4 cells and a recombinant Notch1-IgG fusion protein, and (2) 
fucosylation controls Notch1 receptor density on the surface of an E2a/Pbx1 immortalized 
bone marrow progenitor cell line. These results indicate that fucosylation controls Notch1 




In the effort to fully understand the role of fucosylation in mammals, a mouse model 
with global fucosylation deficiency was generated by disrupting the gene FX that is 
responsible for making GDP-fucose, the only fucose donor in the de novo pathway. A 
thymic atrophy phenotype was observed and analyzed in detail. This phenotype resembled 
the phenotype reported in Notch1 conditional knockout mice, as it exhibited a virtually 
complete loss of mature thymocyte populations. Further, fucosylation-dependent disruption 
of Notch1 signaling has been shown to be the key reason for thymic atrophy in FX(-/-) 
mice deprived off fucose for 4 weeks at the cellular level. In the absence of fucosylation, 
bone marrow progenitors were not able to differentiate into mature T cells, either in vitro or 
in vivo. Moreover, non-fucosylated bone marrow stem cells were not able to express Notch1 
downstream genes in conditions where Notch1 downstream signaling was induced. These 
observations assign an essential role to fucosylation in T cell development and related Notch 
signaling. However, the mechanisms that account for defective Notch signaling coincident 
with the loss of fucosylation remain unknown.  
To pinpoint the roles of fucosylation and fucosylated glycans in Notch signaling, we 
took into consideration the details of Notch signaling and the ways in which fucosylation 
may modulate Notch signaling.  
 
Which Components are Fucosylated in Notch Signaling Pathway? 
Notch signaling is composed of Notch ligands on the signaling sending cells and 
Notch receptors on signaling receiving cells, together with multiple regulators and co-
activators. All of the mammalian Notch ligands and receptors are large transmembrane 
proteins with multiple EGF repeats in extracellular domains (243). 
EGF repeats have several structural characteristics. First, each EGF repeat has 
approximately 40 amino acids with six evolutionarily conserved cysteine residues. These 
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cysteines form three disulfide bonds between C1-C3, C2-C4 and C5 and C6 (244). Second, 
EGF repeats contain Ca2+ binding sites. However, a comparison between the structures of 
Ca2+-containing EGF (245) and Ca2+-free EGF (246) suggest that Ca2+ performs a minor 
role in conformation change. Third, two different types of glycosylation have been found on 
the EGF repeats, O-glucosylation and notably O-fucosylation (15). The O-glucose 
modification occurs at the serine residues of the first and second conserved cysteins of EGF 
repeat with the consensus sequence of C1XSXPC2 (10). More importantly, O-fucose is 
found linking to serine or threonine residue within the putative consensus sequence 
C2XXGG(S/T)C3 between the second and the third cysteins of the EGF repeat (242).  
Potentially, EGF containing proteins are subjected to fucosylation. Because all of 
the Notch receptors and ligands contain multiple EGF repeats, they are all very likely to be 
fucosylated. Haltiwanger and colleagues have proved that Notch receptors (15) and Notch 
ligands (199) are all fucosylated. Other partners of Notch signaling have not yet been 
known to be fucosylated. Thus we focused on three different possibilities: fucosylated 
ligands, fucosylated Notch receptors, or both are required for Notch signaling. 
Two of the three possibilities are easily ruled out, because fucosylation seems not to 
be required for Notch ligand function. As discussed in Chapter II, when wild type bone 
marrow cells were injected into a FX(-/-) recipient off fucose mouse, wild type T cell 
progenitors developed normally in the non-fucosylated environment of FX(-/-) thymus 
when deprived of fucose 4 weeks. As is widely accepted, Notch ligands are expressed on 
the surface of thymic stromal cells and instruct the development of the thymocyte 
progenitors. The fact that non-fucosylated Notch ligands are apparently able to direct 
thymocyte development suggests that fucosylation of Notch ligands may not be required for 
them to induce signal transduction.  
Thus fucosylation on Notch receptors must be critical for proper signaling. Non-
fucosylated Notch receptors may not signal. This is indicated by the experiments discussed 
in Chapter III, in which bone marrow stem cells carrying Notch receptors can only progress 
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through mature T cells in the presence of fucosylation. This conclusion helped us focus our 
efforts on the fucosylation of Notch receptors and to look for the roles of fucosylation in 
Notch signaling regulation. 
 
Where and When does Fucosylation Occur on Notch Receptors? 
As described above, Notch receptors contain EGF repeats where fucosylated 
glycans are added. Fucosylation is one of the post-translational modifications to proteins by 
the enzymes of fucosyltransferases, indicating that the location of fucosylation may be at 
ER, Golgi, cytosol and/or a cellular compartment other than nucleus. O-fucosylation of 
Notch EGF repeats is specifically carried out by protein O-fucosyltransferase 1 (197). The 
location of POFUT1 determines the location of fucosylation.   
POFUT1 was first found located in ER in Drosophila (201), which is very different 
from Golgi-localized fucosyltransferases mediating the addition of N-linked fucosylated 
glycans. The ER-localized site for POFUT1 has been confirmed in mammalian systems 
(36). The ER is one of the most important places for protein synthesis, modification, and 
secretion. For a type 1 transmembrane protein such as a Notch receptor, mRNA is 
transcribed to protein and folded in the ER, while the signaling peptide immediately directs 
the protein localizing across the ER membrane. Notch proteins are very likely to be folded 
during or after synthesis via chaperon, a set of proteins helping polypeptide folding.  
Temporally, O-fucosylation happens in ER in the early stage of protein synthesis, 
before the Notch receptor reaches the Golgi and is subsequently presented on the plasma 
membrane where it interacts with its ligands. There is evidence that POFUT1 also serves as 
a chaperon for the Drosophila Notch, suggesting that fucosylation plays a role in protein 
folding, at least in Drosophila (201).  
 
How does Fucosylation Regulate Notch1 Signaling in Mammals? 
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From the above analysis, multiple roles of fucosylation in Notch1 signaling may 
exist; in Chapter IV two major roles of fucosylation in the regulation of Notch signaling 
have been proposed and tested. 
1) The proposed role of fucosylation in ligand binding: 
Glycans serve many roles, including their role within glycoprotein interactions. One 
of the widely known examples is P-selection glycoprotein ligand 1 (PSGL-1). PSGL-1 has 
a fucosylated moiety that serves as a component recognized by P-selection. Deletion of 
fucose on PSGL-1 abolishes the binding ability of PGSG-1 to its counter receptors. This 
could also be the case for O-linked fucosylated glycans, as they serve as a Notch ligand 
recognition motif on Notch. In flies, mutations of O-fucosylated sites on different EGF 
repeats have shown that EGF11 and 12 are required for the binding of Notch to its ligand. 
These two EGF repeats are required and sufficient for the ligand delta (247). A mutation of 
EGF12 with a substitution of Ala to Serine in order to abolish the fucosylation resulted in 
defects in wing development that are similar to a Notch null phenotype (248). In vitro 
evidence indicates that missing fucosylated glycans of Drosophila Notch protein at EGF12 
enhanced Notch binding to its ligands (248). This observation indicates that, in flies, O-
linked fucosylated glycans regulate the binding affinity of Notch receptors to their ligands. 
However, it remains to be determined whether fucosylation controls the binding of 
mammalian Notch receptors to its ligands. 
Thus in the first part of this chapter, we pursued quantitative methods to characterize 
the binding activity of mammalian Notch1 and its receptors in two individual experiments as 
a function of fucosylation in vitro.  
 
2) The proposed role of fucosylation in Notch receptor folding and secretion: 
Notch receptor secretion was suggested by studies published in 2005 (201). These 
studies introduced Drosophila protein O-fucosyltransferase 1 and showed that this enzyme 
acts significantly as a fucosyltransferase, and also functions as a chaperon. Mutational 
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inactivation of the fucosyltransferase activity of POFUT1 does not seem necessary for 
Notch secretion, indicating that fucosylation is not required for Notch receptor presentation 
on the cell surface in flies. The method of confocal microscopy used in assessing the 
amount of surface Notch receptors in the studies was not satisfying, due to the limited 
number of subcellular regions focused on each time and the non-quantitative nature of this 
technique. However, this piece of information sheds light on, and may potentially contribute 
to new studies in the field of fucosylation.  
Mammalian Notch signaling is more complex than that of Drosophila, given that 
there are more Notch receptors, more ligands, and a more complex mechanism involved. 
Mutation on EGF 27 of mouse Notch1 that abolished O-fucosylated glycans on that site 
reduced the amount of cell-surface Notch (242). These data strongly suggested that 
fucosylated glycans are used in the mammalian system during Notch1 protein folding and 
secretion. However, no similar data have been published yet on the consequences of the loss 
of fucosylated glycans on Notch. Given that O-fucosyltransferase would fucosylate all 
potential sites or none, it is impossible for cells to lose fucosylated glycans only on one 
particular EGF. Thus testing whether Notch secretion is regulated by global fucosylation 
seems essential to understanding the details of mammalian regulatory systems. In the 
second part of Chapter IV, a quantitative biochemical method was used to find out whether 
fucosylation is relevant to the surface presentation of Notch1 receptors. Considering this 
together with the binding studies, we hope that our effort will advance glycobiological 




DNA constructs-Full length mouse Dll4 or Notch1(1-15EGF) was cloned into 
vector pCDNA3.1 containing human IgG1 Fc portion, resulting in a fusion chimera of 
Dll1-hIgG1 or Notch1(1-15EGF) separately.  
Transient transfection- 8x106 HEK 293T cells were plated in a 10-cm dish the day 
before transfection in DMEM medium with 10% FBS. 24ug of DNA and 60ul 
Lipofectamin 2000 (Invitrogen) was diluted separately in 1.5ml of OPTI-MEM medium 
and sat at room temperature for 5 minutes. DNA solution was added to Lipofectamin and 
sat at room temperature for 20 minutes for integration, before being added to the cells. 24 
hours after transfection, attached HEK 293T cells were trypsinized and washed with serum 
free medium (Hyclone) 3 times. Then the cells were plated into 3 150-cm plates for protein 
production. The supernatant was collected 3 days after plating and cells were eliminated by 
centrifugation at room temperature for 15 minutes. To make fucosylated and non-
fucosylated Notch1(1-15EGF), similar procedures were followed for Lec13 cells. Fucose 
was added on the day of transfection and in serum-free medium for CHO cells (Gibco).  
ELISA--The ELISA quantification method for human IgG1 Fc chimeras was set up. 
Each well was coated with 100ul of 2ug/ml anti-hIgG1 (Sigma) at 4°C overnight. After 
being washed 5 times with PBS-0.5%Tween 20, 100ul human IgG (Sigma) in different 
concentrations was first added to develop a standard curve with a 2-hour incubation at room 
temperature. After being washed 5 times, 100ul anti-human IgG Alkaline phosphatase 
conjugated antibody (Sigma) was incubated for 1 hour at room temperature. 50ul of p-
nitrophenyl phosphate (PNPP, Pierce) as the substrate was added for colorimetrical 
detection. After 15 minutes, the reactions were detected by the ELISA plate reader (Bio-
Rad). 
Notch1 fusion protein staining and confocal microscopy- OP9-Dll4 and OP9 cells 
were plated in 25x103 cells/ml in 150mm dishes or on collagen-coated microscope slides 
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and grew for 2 days. OP9 cells in dishes were dissociated by 3mM EDTA at 37°C for 
15min for flow cytometry staining. 70um cell strainers were used to eliminate cell clumps. 
Each 100,000 cells were aliquoted into each staining tube. 100ul of each Notch1(1-15EGF)-
hIgG1 chimera dilution was added to each staining tube in OP9 medium at room 
temperature for 30min. PE-conjugated anti-human IgG was used as the secondary antibody 
for flow cytometry detection. The OP9 and OP9-Dll4 cells on the slides were stained by 
Notch fusion proteins in the same condition as above for 1 hour at room temperature. 
Texas-Red conjugated anti-hIgG was used as the secondary antibody for Notch1, since the 
emission wavelength of Texas-Red does not overlap with that of EGFP expressed by OP9 
cells. Thus when the Argon and HeNe lasers are simultaneously working, the signaling 
leakage from green channel by EGFP would be minimized in the Red channel, so that red 
signals by Notch fusion protein could be sensitively detected. After staining, cells were 
fixed by 4% formaldehyde and mounted for examination (Leica Microsystems Inc). 
Typically a series of 30 pictures were taken from several different regions on the slide from 
the bottom of the cells to the top at about 6um intervals along the z-axis. To minimize the 
biased comparison among different regions of the cells, a picture of overlapped z-stack 
pictures was generated afterwards to show the total signal. 
Ligand fusion protein staining- Dll4-hIgG1 chimera in serum-free culture medium 
was added to cells in a 1:1 dilution with culture medium at room temperature for 30 
minutes. After being washed with the medium, the cells were incubated with a PE-
conjugated anti-human IgG polyclonal antibody. Human IgG was used as a negative 
control.  
Extracellular Notch1 dissociation by EGTA treatment- After being collected, the 
cells were washed twice in Hank’s Balanced Salt Solution with 2.5mM CaCl2 buffer. The 
Notch1 extracellular domain was dissociated by EGTA in TBS buffer in a 37°C water bath 
for 15 minutes. After the cells were centrifuged at 1300 rpm for 5 minutes, the dissociated 
proteins were collected in the supernatant. Cell pellets were treated with 1xRIPA buffer and 
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DNAs were sheared by being passed through an insulin syringe in a cold room. DNA and 
membrane debris were removed by centrifugation at top speed for 30 minutes at 4°C.  
Western blot- Cell lysate or EDTA dissociated proteins with SDS loading buffer 
(Invitrogen) were boiled at 70°C for 10 minutes. Samples were loaded in 15-well 3-8% 
acrylamide gel and transferred to a PMSV membrane overnight. Anti-mouse Notch1 (8G10 
clone, 1:200, Santa Cruz) was used to probe the membrane. After washes, anti-hamster HRP 
(1:5000) conjugated secondary antibody was added. To develop the films, after washing the 
membrane, ECL substrates (Pierce, Supersignal) were added for 1 minute. The membrane 
was stripped by Restore Western Blot Stripping Buffer (Pierce) and blotted by anti-mouse 
beta-actin (mouse monoclonal, 1:10,000, Santa Cruz) as loading controls.  
 
Results 
Our results in Chapter II suggested that the loss of fucosylation diminishes Notch1 
downstream signaling. In this chapter, we further pursued the molecular mechanisms of 
fucosylation-dependent Notch1 signaling regulation. Losing fucosylation may disrupt 
Notch1 signaling in many different ways. It is likely that non-fucosylated Notch1 proteins 
are not presented on the cell surface; thus there are no Notch1 receptors to bind to its 
ligands for downstream signal transduction. We first tried to ask whether losing 
fucosylation perturbed the surface presentation of Notch1 proteins.  
 
The Reduced Surface Presentation of Notch1 in the Absence of Fucosylation 
The role of fucosylation in Notch1 protein secretion was tested by quantitative 
western blot experiments. In these experiments, Homogenous FX(-/-) myeloid progenitors 
were used. These cells were made by transducing the E2a/Pbx1 gene to FX(-/-) adult bone 
marrow progenitors. More specifically, the beta-estradiol response unit controlled E2a/Pbx1 
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gene was inserted into a viral vector pMIG to produce the oncogenic fusion proteins (249). 
Virus was produced by Phoenix E packaging cell lines and collected in supernatant. The 
FX(-/-) bone marrow stem cells were enriched in vivo by 5-fluorouracil treatment and were 
isolated by the depletion of lineage positive cells. These FX(-/-) stem cells were cultured for 
2 days before transduction. After transduction, the transduced cells were selected by long-
term culture and myeloid lineage was driven by the cytokine of GMCSF made by B16 cells 
(249). The expression of the E2a/Pbx1 gene was enabled by the addition of 1uM beta-
estradiol. Only the cells expressing E2a/Pbx1 would exist in the culture and be able to avoid 
dying out. When the culture was 4 weeks old, individual clones were seeded by serial 
dilution methods. These clones were expanded and selected for their uniform GFP 
expression. I discovered 2 independently selected cell lines. These cells were cultured as 
single-cell suspensions at 1x106/ml and fed on a daily basis. The progenitor cells are large 
round suspended cells with large nuclei (Figure 4-1a) and do not express mature 
granulocyte markers, such as Gr-1 (Figure 4-1b). When they were cultured in the absence 
of beta-estradiol, they further differentiated into polymorphonuclear neutrophils (PMNs) 
showing the segmented shape of nucleus (Figure 4-1a) and expressing Gr-1 on the cell 
surface (Figure 4-1b).  
An FX(-/-) myeloid progenitor cell line was first characterized in its ability to bind to 
Notch ligands as a function of fucosylation (Figure 4-1c). Expanded cloned cells were 
originally made in the absence of fucose. They were divided in half and cultured in the 
absence or presence of 1mM fucose in the culture medium. Two days later, the cells were 
collected for staining. PSA staining showed the fucosylation status of the cells right before 
being used for the quantitative western blot experiments. Gr-1 staining demonstrated the 
homogenous progenitor-like developmental stage of these myeloid progenitors with all the 
cells lacking Gr-1 expression. Dll4-IgG chimera binds to fucosylated myeloid progenitors 
much better than the non-fucosylated ones, indicating the presence of non-fucosylated 
Notch1 receptors on the cell surface.  
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EGTA treatment was used to dissociate cell membrane Notch1 proteins, and the 
experimental setup is shown in Figure 4-2. The 8G10 antibody used on the western blot 
was made as targeted against the N terminal of mouse Notch1 (Figure 4-3a). At first, the 
EGTA dilution curve was generated to optimize the dissociation of non-fucosylated Notch1 
proteins (Figure 4-3b). It seemed that 5mM EGTA was enough to dissociate all the Notch1 
proteins on the cell surface, while 10mM EGTA was used to ensure maximum dissociation 
results. Because the FX(-/-) myeloid progenitor cell line was made in the absence of fucose, 
these expanded cloned myeloid cells were cultured in the absence of fucose or in 1mM 
fucose in parallel for 2 days before shedding experiments.  
Dissociated proteins in the supernatants from 1x106 cells were loaded per lane for 
comparison in the presence or absence of fucosylation (Figure 4-3c). Only one form of 
Notch was found in the supernatants, by size as known of extracelluar domain of Notch1 
(ECN). More ECNs from the fucosylated cells were detected than the ECNs from the non-
fucosylated cells. No other forms of Notch1 were detected. The absence of full-length 
Notch1 that reside inside of the cells indicated that the cells were not lysed by EDTA 
treatment.  
 However, in the cell lysate after EGTA treatment, two forms of Notch proteins were 
found. The smaller form of Notch1 by size is most likely to be the ECN sequestered inside 
the cells, perhaps within the protein secretion pathway. More ECN from fucosylated cells 
were found compared to the ECN found in non-fucosylated cells. The larger form of 
Notch1 is the non-processed Notch protein, the so-called full-length Notch1. In the cell 
lysate after EGTA treatment, fewer full-length Notch1 proteins from the fucosylated cells 
were found compared to the full-length Notch1 from the non-fucosylated cells. The 
presence of more naïve and unprocessed Notch1 proteins in non-fucosylated cells indicated 
that there was a defect in the Notch1 protein secretion pathway of the non-fucosylated cells.  
Notably, a size difference was observed between fucosylated-Notch1 forms and 
non-fucosylated Notch1 forms, including ECNs and full-length Notch1. It seemed that 
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fucosylated-glycans on Notch1 EGF domains added a few kilo-Dolton to the protein 
weight, thus they migrated slower in electrophoresis. These results indicate that fucosylation 
is required for Notch1 secretion in mammalian cells. It is very different from the reported 
results in the Drosophila system (201), indicating the more complicated regulatory role of 
fucosylation of Notch signaling in mammals.  
Although in a reduced quantity, there were indeed non-fucosylated Notch1 proteins 
on the cell surface. Since these non-fucosylated proteins presented on the cell surface, did 
they bind to the ligand as well as the fucosylated proteins? Non-fucosylated FX(-/-) 
E2a/Pbx1-immortalized progenitor cells had less binding affinity to the Dll4-hIgG1 chimera 
(Figure 4-1c). However, the reduced binding ability may result from the reduced amount of 
the surface Notch1 proteins that were available to bind to the Dll4 ligand. Thus we took a 
different approach to assess the binding abilities of the fucosylated and the non-fucosylated 
Notch1 proteins.  
 
Non-fucosylated Notch1 Reduced Ability to Bind to its Ligand of Dll4 In Vitro. 
A very precisely controlled experimental system has been designed to investigate the 
influence of fucosylation on Notch1 binding to its ligands (for details see the Discussion). 
OP9-Dll4 cells were used for Notch ligand Dll4 expression. The cells were dissociated 
from the plate by EGTA treatment. Because the Ca2+ ion does not contribute to forming the 
structure of EGF repeats, depleting Ca2+ by EGTA may not able to change the conformation 
of Dll4 proteins that contain only 8 EGF repeats. Moreover, Notch ligands are 
transmembrane proteins with no S1 cleavage (i.e. not heterodimer), which suggested that 
Notch ligands could not be dissociated by EDTA treatment. Thus the low concentration of 
the EGTA treatment is a “safe” method for generating individual OP9 cells bearing Notch 
ligand without losing Notch ligand proteins on surface.  
A Notch1(1-15EGF)-hIgG1 chimera was made in vitro, in FX-deficient CHO cells 
(CL17), cells via transient transfection by Lipofectamin 2000. Cells were trypsinized 24 
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hours after being transfected and expanded in serum-free medium for protein secretion. The 
fucosylated Notch1(1-15EGF)-hIgG1 chimera was secreted by the transfected CL17 cells 
in the presence of 1mM fucose. The non-fucosylated Notch1(1-15EGF)-hIgG1 chimera 
was secreted by the transfected CL17 cells in the absence of fucose.  
A human IgG specific ELISA was developed and optimized to measure the 
concentration of each chimera. IgG Fc portion of the chimera naturally dimerized, thus one 
hIgG1 chimera protein has two Fc sites available for antibody binding. The coating 
antibody for capture recognized one Fc site. The other Fc site was recognized by Alkaline 
Phosphate conjugated anti-human IgG antibody for detection (Figure 4-4a). A standard 
curve was developed by using the serial dilutions of purified human IgG Fc proteins. The 
O.D.405 readings were plotted versus different concentrations of chimera, and the resulted 
curve was linear-regressed (Figure 4-4b). The diluted Notch1 chimeras in this assay had 
readings in this linear range and the original concentrations were calculated according to the 
dilution factors. Finally, the Fucosylated and non-fucosylated Notch1 (1-15EGF) chimeras 
were normalized to 1800ng/ml, in order that the same molar of the proteins were made in 
serial dilution and were used in later experiments.  
OP9-Dll4 cells and OP9 cells were expanded in culture for two different 
experimental setups (illustrated in Figure 4-5). The same batch of cells was used for 
staining on slides and in tubes to ensure the same number of Dll4 ligands on the cell 
surface. The same amount of the fucosylated or non-fucosylated Notch1 chimeras were 
used to test the binding abilities to the same number of Dll4 ligands.  
In flow staining, OP9-Dll4 cells were stained by fucosylated-Notch1(1-15EGF)-
hIgG chimera or non-fucosylated Notch1-hIgG chimera in different concentrations (Figure 
4-6). Each pair of data showed that the same concentration of the fucosylated chimera and 
the non-fucosylated chimera were used and compared in parallel. OP9-Dll4 cells bound to 
the fucosylated-Notch1(1-15EGF)-hIgG more than the non-fucosylated Notch1(1-
15EGF)-hIgG in all concentrations tested. These results indicate that the non-fucosylated 
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Notch1(1-15EGF)-hIgG1 has weaker binding affinity than the fucosylated chimera. As 
controls, OP9 cells were stained in the same experimental setup but showed binding abilities 
to neither the fucosylated nor the non-fucosylated Notch1(1-15EGF)-hIgG chimera (data 
not shown). 
The mean fluorescence intensity of stained OP9-Dll4 cells in Figure 4-6 was plotted 
versus the different concentrations of Notch1 chimera used in staining (Figure 4-7). Low 
concentration points were plotted by linear regression, with the regression equations shown 
by the lines (Figure 4-7a). These data fit the linear curve with a coefficient of determination 
(R2) very close to 1.00 (perfect fit), suggesting a precisely controlled experimental platform. 
The fucosylated Notch1 chimera staining curve had a greater slope (1.379) in the linear 
range, indicating a greater binding affinity than non-fucosylated Notch1 chimera 
(slope=0.49).  
Figure 4-7b shows the full range of the different concentrations of chimeras used. 
Strikingly, the non-fucosylated chimera reached a binding plateau (MFI=319.59) of about 
half that of the fucosylated one (MFI=592.99), indicating different binding avidities of Dll4 
to different forms of Notch1. These observations have been confirmed by an independent 
experiment of the surface plasmon resonance (Jeongsup Shim and John Lowe, unpublished 
data).  
Further, confocal microscopy was used to confirm this result in an independent 
experimental setup. Figure 4-8 showed the representative area of each staining slide with a 
series of Notch1 chimera concentrations on OP9 and OP9-Dll4 cells. Notch1 chimera 
bound to Dll4 on the cell surface was represented by the red signals along the edge of the 
cells. Green signals indicated the intracellular region, since EGFP proteins are soluble and 
restricted within the plasma membrane. The co-localization of red and green signals was 
never observed, thus Notch1 proteins bound outside of the cells were not co-localized with 
EGFP sequestered inside the cells, indicating that there was no leak on the cell surface. In 
low concentrations, the Notch1(1-15EGF) chimera did not bind well regardless of whether 
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it was fucosylated. This may be due to the sensitivity of the instrument, since flow 
experiments showed the binding in low concentrations.  
When cells were stained by 180ng/ml of chimeras, the intensity difference was 
shown that OP9-Dll4 cells bound more fucosylated Notch1 chimeras than the non-
fucosylated chimeras. OP9 cells are not stained by any concentration of the fucosylated or 
non-fucosylated Notch1(1-15EGF)-hIgG1 chimeras as shown in the right panels, indicating 
that binding to the chimeras to OP9-Dll4 cells was specific to the Dll4 ligand. These 
observations have been confirmed by three individual experiments. 
The above results from two independent experiments indicate that the loss of 
fucosylation on Notch1 reduces its binding ability to the ligand Dll4. This observation 
corresponds to the loss of Notch1 downstream signaling in FX(-/-) hematopoietic 
progenitors and the loss of Notch1-dependent T cell development in the FX(-/-) thymus. 
This observation also indicates that the monosaccharide fucose plays a very important role 




A Cell Line for Cell Surface Protein Comparison 
To compare cell surface protein expression in a function of fucosylation, a specific 
cell line was pursued. First, these cells have to be a homogenous population that has global 
fucosylation deficiency. This will ensure the precise comparison in the quantitative methods 
in the function of fucosylation. We currently have three homogenous populations available 
to use: 1) Lec13 (mutation on GMD) and CL17 (mutation on FX) are Chinese hamster 
ovary cells with global fucosylation deficiency and have been used for decades in various 
research groups; 2) FX(-/-) MEF (Mouse Embryonic Fibroblast) was made from FX(-/-) 
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embryos in our lab and used in our previous experiments; 3) Four years ago, I made an 
immortalized myeloid progenitor cell line from FX(-/-) adult bone marrow stem cells, which 
is also a potent choice for the quantitative experiments. 
Second, this cell line will be a progenitor population in hematopoietic development. 
Lec13 and CL17 cells were made from the hamster ovary, which is not relevant to the blood 
system. MEF cells are fibroblasts involved in hematopoiesis by their ability to support 
embryonic stem cell differentiation. So we could exclude Lec13, CL17 and FX(-/-) MEF 
cells from our pool of selections.  
Third, there have to be a constant level of Notch proteins expressed by the cells in 
order to ensure that only one variable of fucosylation is tested. The binding ability of FX(-/-
) myeloid progenitors to Notch ligand Dll4 was tested first (Figure 4-1). In the presence of 
fucose, FX(-/-) myeloid progenitors were bound to the Dll4-hIgG1 chimera, indicating the 
existence of Notch1 receptors. This observation encouraged us to test FX(-/-) myeloid 
progenitors in the surface Notch1 study. Thus only the immortalized FX(-/-) myeloid 
progenitors were chosen for our experiments.  
 
A Feasible Experimental System for Binding Assay 
In order to assess the binding activities of non-fucosylated Notch1 receptors to their 
fucosylated ligands, it is very important to find out the experimental platform suitable for 
this defined question. The cell-based systems have long been used in binding assays and 
may closely represent what is happening in vivo. So a cell-based system with Notch1 
expressed is desired, while the Notch ligand could be used to quantify the binding ability of 
Notch1 proteins in the function of fucosylation.  
At first, to closely replicate the progress of T cell development, T cell progenitors 
were proposed with great interest in having Notch1 receptors on the surface. As discussed 
in the introduction chapter, the earliest T cell progenitor in bone marrow has not yet been 
defined, which made it impossible to isolate such populations for our study. Stem cell 
 105 
derivatives from certain in vitro OP9 co-culture systems were able to differentiate to T cells, 
as described in Chapter III, indicating their potential for the binding assay. However, the 
complexity of multiple Notch ligands on multi-potential progenitors cells made it very hard 
to interpret our results while accessing their binding ability to Notch ligand chimeras, 
especially in a quantitative way.  
Thus a homogenous population was preferred for our purpose. The FX(-/-) 
E2a/Pbx1 progenitor cells are homogenous and express Notch1 on the cell surface. We 
preferred for our experiments, however, for the amounts of fucosylated and non-fucosylated 
Notch1 proteins on the cell surface to be different. Thus a fair comparison cannot be made 
due to various amounts of receptors on the cell surfaces.  
In light of the difficulties we met in the above attempts, a reversible system was 
designed. A cellular system bearing Notch ligands was proposed with the availability of 
fucosylated and non-fucosylated Notch1 chimeras made in vitro. Notch ligand transduced 
OP9 cells were ideal for us to use in the binding assay because of the purity of cells and the 
equivalent amount of Notch ligand presented on the cell surface. Fucosylated and non-
fucosylated Notch1 chimeras were quantified in vitro by the ELISA system, which is highly 
sensitive. The same molars of fucosylated and non-fucosylated chimera were used; thus the 
only variable in the assay system was the presence or absence of fucosylated glycans on 
Notch1 proteins.  
 
The Dual Functions of Fucosylation in Notch1 Signaling 
Haltiwanger and colleagues have reported their study of fucosylated sites on Notch1 
receptors in mammalian cell lines in vitro (15, 242, 250). Three EGF repeats on Notch1 
receptors were extremely evolutionarily conserved across different species (251). Several 
other EGF repeats on Notch1 were highly evolutionarily conserved. They made 8 different 
mutants, in which one EGF repeat was mutated by using Ala substituting Serine or 
Threonine to delete the site O-fucose may link to. Among the 8 mutants studied, only 3 of 
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them resulted in aberrant Notch1 downstream signaling. Mutation on either EGF 12 or 
EGF 27 led to decreased downstream signaling triggered by either Dll1 or Jagged1. On the 
contrary, mutation on EGF 26 elevated downstream signaling induced by either Dll1 or 
Jagged1. These studies suggest the important roles of fucosylated glycans on Notch 
receptors in the regulation of its signaling abilities.  
However, it is not known yet whether losing fucosylated glycans on any of the EGF 
repeats of Notch1 receptors leads to altered ligand-binding abilities. Moreover, these studies 
were focused on individual EGF domains and/or the fucosylated glycans on these particular 
domains. There was no evidence yet that showed what would happen if all the fucosylated 
glycans were lost at one time. Since POFUT1 is the enzyme fucosylating all possible sites 
on EGF repeats, it is not very likely that only one EGF repeat is not fucosylated while the 
others are. It would be more likely that all of the possible fucosylated sites are fucosylated 
or not fucosylated. It is important to find out how losing fucosylation on all of the EGF 
repeats affects the signaling and functions of Notch1.  
N-glycans have been studied for a long time and they are known as essential 
components of the binding pockets of lots of proteins, including PSGL-1. It is not clear yet 
if O-fucosylated glycans contribute to the structure of binding pockets in the mammalian 
system. Our results from Figure 4-3 strongly indicate that a non-fucosylated Notch1 form 
exists in nature. The presence of non-fucosylated Notch1 on the cell surface indicates that 
losing fucosylation alone cannot fully stop Notch1 secretion. This result seems to be 
different from that in Drosophila, in which losing fucosylation did not perturb the secretory 
pathway of Notch1 proteins (201).  
The amount of Notch1 presented on the cell surfaces was evident independent of the 
fucosylation status of the cells (Figure 4-3). Dll1 density was shown regulating Notch1 
signaling strength in vitro (252). But the density of Notch ligands within the thymus is 
more likely to be constant. Conversely, it is very likely that the density of Notch1 on signal 
receiving cells actually controls the signaling strength. Thus regulating Notch1 receptor 
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density on T cell progenitors could be a very efficient and direct way to regulate the T 
lineage commitment. These results suggest the regulatory role of fucosylation in controlling 
Notch1 signaling strength by attenuating the secretory pathway of Notch1. 
The binding ability of the non-fucosylated form of Notch1 was greatly reduced 
compared to the fucosylated forms of Notch1 (Figure 4-7 and Figure 4-8). Even when non-
fucosylated Notch1 was provided at high concentration, the binding of non-fucosylated 
Notch1 to Dll4 could not be restored to the level of fucosylated Notch1. In the kinetic 
aspect, the result showed in Figure 4-7 is the statistical summary of an equilibrated status 
that included dynamic binding and dissociating. Some of the ligands were dissociating from 
the receptor at the moment others were binding to the receptor. The bound-ligand detected 
from our assays actually represents the chance of Notch1 binding to OP9-Dll4 cells.  
When the Notch1 chimera concentration was increased, the chance of Notch1 
chimera binding to ligands was increased. However, the ratio of Notch1 chimera 
dissociating from OP9-Dll4 cells was also simultaneously increased. When providing 
enough Notch1 chimeras, dissociating Notch1 and binding Notch1 reached a constant level. 
In this situation, no more Notch1 was able to bind to the OP9-Dll4 cells, since all the 
binding pockets were occupied. The plateau in the binding curve shown in Figure 4-7 
represents the nature of binding pockets themselves. When the binding pockets were 
fucosylated, the ligands were not likely to be dissociated as fast as the ones that bound to 
the non-fucosylated binding pockets. It is also possible that dissociation was the same for 
non-fucosylated and fucosylated ligands, while fucosylation greatly increased the speed at 
which ligands were able to bind.  
In conclusion, fucosylation in mammalian system plays important and complex 
roles in the regulation of Notch1 signaling. Mammalian cells can quickly reduce Notch1 
downstream strength by lowering the fucosylation level, thus non-fucosylated ligands would 
be stuck during transportation from ER to Golgi. The cell surface fucosylated receptors 
were reduced during turnover. Newly synthesized non-fucosylated Notch1 proteins were 
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presented on the cell surface with difficulty. Even non-fucosylated Notch1 proteins were 
able to bind and be presented on the cell surface; their reduced ability to bind to their 
ligands substantially decreased the Notch1 downstream signaling strength. As a result, the T 
lineage commitment of hematopoietic progenitors was disrupted.   
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Notes to Chapter IV 
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Figure 4-1: Characterization of E1a/Pbx1 transduced 
FX(-/-) bone marrow myeloid progenitor cell lines. a. 
Pictures of the cells cultured in the presence of beta-estradiol 
(Left) and in the absence of beta-estradiol (Right) for 6 days. 
Blue staining shows the nucleus. b. Cell surface markers of 
myeloid progenitor cells in presence or absence of beta-
estradiol. (No-fucose added in the culture) c. Staining and 
binding experiments on myeloid progenitors cultured with beta-
estradiol. Fucosylation status of the cells is shown by PSA 
staining. Arrested cell differentiation statuses are indicated by 
Gr-1staining. Notch-ligand Dll4-hIgG1 chimera binds to FX(-/-
) myeloid progenitor cells in the presence of fucose much better 


















Figure 4-2: Illustration of quantification of Notch1 
different forms. Notch1 protein is made in ER and modified 
by POFUT1. Then during secretion pathway, Notch1 proteins 
moved through Golgi, where it is cleaved by Furin enzyme, 
known also as S1 cleavage to form the heterodimer. EDTA 
dissociate Notch extracellular domain from cell surface. Panel a 
shows the fucosylated cells while panel b shows the non-
fucosylated cells. Panel c and d shows the Notch1 proteins in 
supernatant and cell lysate after EDTA treatment in fucosylated 
























Figure 4-3: Quantification of Notch1 in different cellular 
locations. a. Anti-Notch1 antibody 8G10 specifically binds to 
mouse Notch1 EGF33 to LIN repeat 1 (shown in panel a as in 
non-fucosylated Notch1 forms). FX(-/-) E2a/Pbx1 transduced 
myeloid progenitor cell line was made in the absence of fucose. 
b. EDTA in Notch dissociation experiment has been titrated on 
those cells in the absence of fucose while maximum amount of 
Notch1 in supernatant detected in 10mM EDTA treated 
samples. c. The fucosylated and non-fucosylated FX(-/-) 
E2a/Pbx1 transduced myeloid progenitors were treated with 
10mM EDTA. Supernatant collected after treatment was loaded 
in left lanes. Cells collected after EDTA treatment were lysed 
and denatured before loaded in right lanes. Anti-Notch1(8G10) 
shows the Notch forms as indicated in upper western blot. The 
same blot was stripped and blotted with anti-beta-actin to show 












Figure 4-4: Standard curve of hIgG1 Fc chimera ELISA. 
Top panel shows the experimental setup. Lower Standard panel 
shows one of the representative standard curves using human 
IgG1 Fc. In details, Fc dimerized hIgG1 was bought from 
Sigma and diluted to different concentrations for a standard 
curve in quantification of soluble Notch1(1-15EGF)-hIgG1. 
Linear regression was used to develop a correlation of 
concentration to O.D. 405. R2 represents the approximation of 
data points to the linear regression curve, and in this case, 
0.9959 of R2 has shown a very accurate linear relationship 







Figure 4-5: Designs of quantitative binding experiments. 
OP9-Dll4 cells were expanded in culture first. Some of the OP9 
cells were directly plated on microscope cover slides for staining 
with fucosylated or non-fucosylated Notch1 (1-15EGF)-hIgG1 
chimera (Bottom). Some of the cells were seeded in very low 
density to be detached by EDTA treatment. Single cell 
suspension was used for fucosylated or non-fucosylated 







Figure 4-6: Fucosylated Notch1 has a higher binding 
affinity to Delta-like 4 than does non-fucosylated Notch1. 
Top left panel shows control staining of hIgG1 to OP9-Dll4 
cells. Different concentration of fucosylated Notch1(1-15EGF)-
hIgG1 (shown as +fucose panels) and non-fucosylated 
Notch1(1-15EGF)-hIgG1 (shown as –fucose panels) were used 
as indicated in flow cytometry staining. In each defined 
concentration, OP9-Dll4 cells are stained better by the 






Figure 4-7: OP9-Dll4 cells have different affinity and 
avidity to fucosylated and non-fucosylated Notch1(1-
15EGF)-hIgG1 chimera. Mean fluorescence of intensity 
(MFI) of each flow sample in previous figure was plot with the 
increasing concentrations. a. Lower concentration rage (1-
180ng/ml) MFI points showed linear fashion. Slopes represent 
the affinity of OP9-Dll4 to different binding partners. b. 
Binding of non-fucosylated Notch1(1-15EGF)-hIgG1 to OP9-
Dll4 cells reached a lower plateau than fucosylated chimera, 










Figure 4-8: Dll4 binds to fucosylated Notch1 with better 
affinity confirmed by confocal microscopy. OP9-Dll4 cells 
were plated on microscope cover slide two days before staining. 
Left panels show OP9-Dll4 cells with right panels showing 
control OP9 cells. OP9 cells are not stained with any of Notch1 
chimera in any concentration. OP9-Dll4 cells show better 
staining in low concentration to fucosylated Notch1(1-15EGF)-





Glycobiology is still a young field compared with protein biology and nucleic 
biology. Although it was estimated that 80% of proteins are glycosylated, our knowledge of 
these sugar structures has remained limited. Searching on the NCBI pubmed database, the 
entries returned by “glycan” amounted to about one third of the publications returned by 
“DNA”, and one tenth of the publications returned by “protein.” From these numbers, 
and given the fact that fewer labs focus on glycobiological research, it is very possible that 
the scientific community has underappreciated carbohydrates and the carbohydrate research 
for a long time (253). The study of glycobiology is complicated by its emphasis it places on 
three different aspects: structure, biosynthesis, and biology. Scientists new to the field may 
first experience consternation at the complex linear and branching structures, and the 
elaborate biosynthetic procedures. Exploring the biological functions of polysaccharides 
must take into account the required knowledge base of the structures and of biosynthesis. In 
the past decades, our understanding of the biological functions of carbohydrates has been 
greatly enhanced by many scientists such as ourselves, enchanted by the concealed wonders 
that may lie ahead.  
Fucose biology was studied as early as the 1960s. The earlier efforts focused on the 
biosynthesis of GDP-fucose, the fucose donor for all fucosyltransferases. With the 
identification of various fucosylated structures, the functions of these glycans were brought 
to Dr. John Lowe’s attention. Taking the approach of genetically engineering mouse 
models, Dr. Lowe and his colleagues successfully disclosed the roles of many fucosylated 
structures in the immune system. One of his prominent works has focused on the glycans 
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modified by fucose attached in the alpha-1,3 anomeric linkage and on the 
fucosyltransferases responsible for their synthesis. In the initial required step during the 
process used by leukocytes when migrating from the blood to extravascular site of 
inflammation, fucosylated structures on selectin ligands are required in leukocyte-selectin 
interactions. Encouraged by the functions discovered, a global fucosylation-deficient mouse 
model was made in order to uncover more functional roles of fucose-containing structures.  
 
Novel Developmental Functions of Fucosylated Glycans 
A genetically engineered mouse model, FX(-/-) mice, was made by the disruption of 
the FX locus to silence the de novo GDP-fucose synthetic pathway (Figure 2-1). The 
salvage pathway of GDP-fucose synthesis enables the manipulation of fucosylation status 
in these mice. By the time of fucosylation loss, each organ of FX(-/-) was extensively 
examined. The thymus from FX(-/-) mice off fucose was shown to be much smaller than 
those of their littermates kept on a fucose-supplemented diet during the loss of fucosylation 
(Figure 2-2). This finding revealed a novel phenotype of FX(-/-) mice: thymic atrophy.  
In order to find out the reason for this thymic atrophy, it is important to examine the 
cellular components within the thymus. The functional role of the thymus in physiology is 
to support the differentiation of T cells. The great majority of the cells in thymus are T cells. 
Multiple cell types, including T cells, epithelial cells, and myeloid cells could be found. 
Thus, cellular components other than T cell in FX(-/-) thymus were considered as the 
supporting environment for thymocyte development (218). To simplify our study: cells in 
thymus are considered to be two groups, the thymocytes (T cells) and other cell types 
(thymic environment). The thymic atrophy defect may be caused by the defects exhibited by 
the thymocytes, or on the thymic environment, or on both.  
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Since thymic size in FX(-/-) mice off fucose decreased greatly, it is most likely that 
the majority of T cells are lost in the thymus. The very first approach was to count the total 
thymocyte numbers from the thymus of FX(-/-) mice upon the time of fucosylation loss. 
Surprisingly, thymocytes were lost when fucosylation was shut off for 4 weeks in FX(-/-) 
mice (Figure 2-2). Although many cell types could be found within thymus, thymus is the 
organ specialized for T cell development. In a wild-type thymus, more than 90% of total 
thymocytes are T cells in different stages of development. Further, T cell populations were 
enumerated in total thymocyte population and refined by their stages during the 
developmental pathway. Mature CD4+CD8a+ T cells were almost completely lost when 
fucosylation was disabled in FX(-/-) mice (Figure 2-3). Early T cell progenitors were also 
missing in FX(-/-) mice off fucose for 4 weeks (Figure 2-4, 2-5, 2-6). These results 
strongly suggested that T cell development was blocked in the absence of fucose.  
It is also likely that defects may occur on any of those cells that eventually harmed T 
cell development within the FX(-/-) thymus in the absence of fucosylation. For normal 
ontology to occur, thymocytes must physically interact with thymic epithelial cells in the 
cortex and the medulla (164). Disruption of thymic epithelial cell expansion in Nude mice 
resulted in the cystic structure made up of epithelial sheets instead of the meshwork three-
dimensional structure in normal mice (254-257). Thymocyte development was greatly 
reduced in nude mice (258). Moreover, the soluble growth factors and cytokines within the 
thymus are also required for thymic development. As one example, mice lacking both 
receptor tyrosine kinase (c-Kit) and the common cytokine receptor gamma chain have 
severe thymic atrophy with completely abrogated thymocyte development (259).  
Thus it is very important to examine the thymic environment of FX(-/-) mice. Wild-
type bone marrow stem cells were introduced into FX(-/-) mice after their being off fucose 
for 4 weeks. Firstly, the emergence of donor wild-type cells in the FX(-/-) off-fucose 
thymus proved that the thymic epithelial cells have no defect upon receiving bone marrow 
progenitors in the absence of fucosylation. Secondly, mature donor T cells identified in the 
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recipient mice proved that the thymic environment is capable of supporting thymocyte 
development.  
These observations strongly suggest that possibilities other than defects on 
thymocytes are excluded in the absence of fucosylation. The non-fucosylated T cell 
progenitors are not capable of differentiating to mature T cells. Cell autonomous defects are 
responsible for thymic atrophy in FX(-/-) when fucosylation is disabled. This physiological 
function role of fucosylation has not been reported yet in previous literature. In conclusion, 
a novel functional role of fucosylation in thymocyte development has been identified in 
FX(-/-) mice.  
 
The Required Presence of Fucosylation in Signaling Events During 
Thymocyte Development 
The observations and conclusions in Chapter II raised a very interesting question: 
how does loss of fucosylation result in the disruption of thymocyte development? 
Thymocyte development is a highly controlled process in which multipotent blood stem 
cells become specialized into T lymphocytes. The differentiation procedures are intricately 
regulated involving changes in many aspects of cell shape, size, polarity, metabolic activity, 
and gene expression profiles. T cell development is controlled by sequential signaling 
events that eventually turn on many gene expressions, including CD4 and CD8. Genes 
specifically expressed in multipotent progenitors are shut down during this process. 
However, fucosylation is a biochemical event concerning the macromolecules inside the 
inner compartments of the cells. How does a biochemical modification to substrates 
influence a strictly controlled developmental process? Fucosylation has to change the 
characteristics and functions of some proteins or lipids involved in T cell differentiation. 
Only through cellular signaling events could a developmental procedure be stopped. To 
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answer this question, a bridge of cell signaling has to be found to bridge the gap from a 
chemical modification procedure of fucosylation to the fundamental process of the cells.  
Biological developmental procedures are tightly regulated by cellular events both 
temporally and spatially in order to formulate organisms. During the differentiation of the 
cells, the programmed events take place in response to the surrounding environment. 
Cellular response is triggered by the signals transduced from outside the cell to inside. 
Similar to all other developmental procedures, T cell differentiation is precisely regulated by 
numerous transcription factors and signaling pathways, including E2a, hematopoietic 
transcription factor PU.1, growth factor independence (Gfi)-1, T cell factor (TCF)-1, Runx 
factors, and the Notch1 signaling pathway (260). Many of these transcription factors are 
also used in many other lineage specifications (261). Most of them promote T cell 
development through Notch signaling. It was thought that Notch signaling has to be “on” 
all the time during T cell development in order to restrain the latent diversionary effect of the 
other factors involved (260). Very luckily, among all these transcription factors and 
signaling participants for T cell differentiation, only Notch receptors and ligands are 
fucosylated. This indicates that Notch signaling is the “bridge” we sought to link 
fucosylation to T cell development. Fucosylation controls T cell development through its 
influences on Notch signaling. Our results in Figure 3-6 have proven that the presence of 
fucosylation turns on Notch1 downstream genes and T cell specific transcription factors.  
On the other hand, fucosylated glycans related to thymocyte development were 
searched for in all known fucosylated proteins. Hundred of proteins are potentially 
fucosylated in a N-linked and/or O-linked fashion mediated by different 
fucosyltransferases. The fucosylated proteins are categorized in two groups roughly, N-
fucosylated proteins and O-fucosylated proteins. N-linked fucosylation is mediated by 
several different fucosyltransferase, encoded by FUT1, FUT2, FUT3, FUT4, FUT5, FUT6, 
FUT7, FUT8, FUT9, FUT10 and FUT11. However, no reported thymic abnormalities were 
found in known knockout mice from the genes above. Then O-link fucosylated proteins 
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were examined extensively. Some of EGF domains are fucosylated by protein O-
fucosyltransferase 1 (POFUT1). Many other proteins containing TSR domains are O-
fucosylated by POFUT2. Among all of these proteins, Notch1 stood out as the most 
promising candidate because it is involved in the regulation of T cell development.  
This conclusion has been further confirmed by comparing thymic abnormalities in 
detail in the following experimental models: 1) Notch1 conditional knockout mice and FX(-
/-) mice off fucose both had a sizable loss of mature T cell subsets. Notch1 conditional 
knockout mice had a residue Notch1 gene expression that cannot be ignored. Thus the 
complete loss of CD4+CD8a+ T cells was not seen in Notch1 conditional knockout mice. 
Although the thymic phenotypes resulting from fucosylation loss are not exactly the same 
as the ones resulting from the loss of Notch1 receptors, it has been strongly suggested that 
T cell progenitors without fucosylation behave to a large extent like the ones without 
functional Notch1 receptors. 2) RBPJ conditional knockout mice also showed a sizable loss 
of mature T cell subsets. These mice lack the Notch1 signaling pathway and display 
phenotypes similar to the Notch1 conditional knockout mice. 3) DNMAML1 transduced 
bone marrow cells lack Notch1 downstream signaling in early differentiation stages. These 
cells cannot progress through DN1a-b stages. 4) DN2 and DN3 cells require Notch1 
signaling to maintain T lineage specification and progression (214, 262). In the absence of 
fucosylation, DN2 and DN3 cells were greatly reduced in the FX(-/-) thymus, indicating the 
loss of Notch1 signaling.  
Although other possibilities may exist, from the above evidence it is most likely that 
fucosylation controls T cell development through modulating Notch1 signaling. Our 
experimental results have supported this hypothesis. Moreover, Notch1 signaling is not 
transduced in T cell progenitors in the absence of fucosylation. This result provided direct 
evidence that fucosylation controls the Notch1 signaling pathway. It is a new function for 
fucosylation in glycobiology and developmental studies and emphasizes the important 
regulatory roles of fucose in nature.  
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Multiple Molecular Functions of Fucosylated Glycans 
The studies presented in Chapter II and Chapter III reached the conclusion that 
fucosylation controls Notch1 signaling transduction and thus influences T lymphocyte 
development. The molecular mechanisms of fucosylation controlled Notch1 signaling were 
focused on in Chapter IV. This part of study shifts from the cellular level to the level 
defined by molecular biology. Our effort included the applications of recombinant DNA 
technology, protein quantification, functional studies of proteins, and cell imaging.  
Kenneth D. Irvine and colleagues have contributed to Notch signaling in Drosophila 
since early 1990. In their earlier studies, they focused extensively on the formation of 
Drosophila wings (263). During this developmental process, the interactions between dorsal 
and ventral cells are required. A soluble protein that modulates dorsal and ventral cells was 
identified and named Fringe (264). Other researchers have found that Serrate (265), Delta 
(266) and Notch (267) also modulate the wing disk formation of Drosophila. Serrate and 
Delta were shown signaling through Notch during wing development (266, 268). The Notch 
signaling then has been set up with Notch proteins as the receptors and Serrate/Delta as the 
ligands. Fringe modulates the Notch signaling pathway through a cell-autonomous 
mechanism (269). The basic scheme of Notch signaling has been set up.  
O-fucose was first identified on the EGF domain of factor XII (270) and was soon 
found on the EGF domains of mammalian Notch (18). A few years later, Fringe was found 
modulating the Notch-ligand interaction (269) through a glycotransferase activity (271). It 
turned out to be a beta1,3 N-acetylglucosaminyltransferase activity that initiates the 
elongation of O-linked fucose residues attached to epidermal growth factor-like sequence 
repeats of Notch (18). Further, studies from the Irvine lab have shown that O-fucose may 
regulate Notch signaling in wing development (25). O-fucosyltransferase was cloned (25) 
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and shown to have chaperon activity in Notch receptor folding (201). Losing fucosylation 
does not disturb the secretion of the Notch receptor in Drosophila (201).  
In the mammalian system, the chaperon activity of POFUT1 has not yet been 
reported. If mammalian Notch1 were folded in the same way as that of Drosophila, losing 
fucosylation would not alter the secretion of Notch1. In FX(-/-) mice off fucose, Notch1 
receptors accumulated in ER  in the full-length format (Figure 4-3), indicating an important 
role of O-fucose in mammalian Notch1 folding.  No quantitative evidence has shown that all 
of the Drosophila Notch receptor stuck in Golgi. Our results showed that there were little 
non-fucosylated Notch1 receptors on the cell surface that potentially interacted with their 
ligand (Figure 4-3). Non-fucosylated Notch1 was also observed in multipotent progenitor 
surfaces in the absence of fucose (Yunfang Man, Bronia Petryniak, John Lowe, unpublished 
data), which excludes the artificial abnormalities of E2a/Pbx1 cell line. However, the 
numbers of non-fucosylated proteins on cell surfaces were scarce compared to those of 
fucosylated Notch1 (Figure 4-3). Thus, different from Drosophila, mammalian cells require 
fucosylation to present Notch1 on the cell surface.  
The Notch1 receptor without fucosylated glycans has lowered binding abilities to 
the Dll4 ligand. One possibility is that non-fucosylated Notch1 receptor is properly folded, 
but that the binding pocket on Notch1 is not in the right shape, due to having lost 
fucosylated glycans. Dll4 binds to the binding pocket with less affinity. Another possibility 
is that the non-fucosylated Notch1 receptor is not properly folded. Dll4 binds to other parts 
of Notch1 (within 1-15EGF). Our results could not differentiate the conformation changes 
of the Notch1 receptor. Future studies are required to answer this question. By NMR and 
X-Ray crystallography, the structures of Notch1 could be obtained to compare the 
conformation of fucosylated Notch1 with non-fucosylated Notch1 in the near future.  
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A Regulatory Mechanism for Maintaining T cell Generation 
Our results in the above chapters strongly suggested that T cell generation depends 
on the cellular fucosylation level and on the proper transduction of Notch1 signaling. 
Attenuating the cellular fucosylation level seems able to adjust the surface Notch1 receptors 
presented. By presenting non-fucosylated Notch1 on the cell surface, the ligand-binding 
abilities of signaling receiving cells are reduced. Further multipotent progenitors adapt 
lineage specifications other than T cells.  
We proposed a possible regulatory pathway to balance T cell development in the 
thymus. Since the expression of Notch1 ligands on thymic stromal cells occurs at a 
constant level, multipotent progenitors are differentiated in the thymus. When Notch1 
signaling is constitutively active, these progenitors are enforced to differentiate along the T 
cell pathway. However, cells other than T lymphocyte subsets were identified within the 
thymus. Since Notch1 signaling is required for multiple transitions within the thymus, 
multipotent progenitors have several chances to quit from the T cell differentiation pathway 
and are quickly differentiated into other cell types, including B cells. Immature and mature 
B cell subsets were identified within the normal thymus (155). Losing Notch1 signaling led 
multipotent progenitors to adopt the B cell fate within the thymus (78). These observations 
indicate that when T cells were surfeit, B cells would be generated within the thymus. 
Natural killer cells were found within thymus and for a long time it was thought they were 
being recruited from the peripheral repertoire (272). More evidence showed that thymic 
natural killer cells developed in situ (273). DN2 cells are able to adopt the NK cell lineage 
that is normally suppressed by Notch1/ligand interaction (262). It is very likely that these 
cell types other than T lymphocyte are generated as the result of decreasing T cell 
generation.  
Thus there might be a feedback loop to prevent the excessive generation of T cells, 
also preventing T cell lymphoma. Excess or an absence of T cells in the periphery may 
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signal multipotent progenitors before their entry to the thymus. A possible feedback target 
is the protein O-fucosyltransferase 1 residing in the ER in these progenitor cells. By 
attenuating the fucosyltransferase activities of POFUT1, the Notch1 signaling strength is 
adjusted accordingly (Figure 5-1). Whenever more T cells than sufficient are generated 
around the periphery, multipotent progenitors in the blood may receive a signal to decrease 
the O-fucosylation level.  POFUT1 in multipotent progenitors may be deactivated by 
various methods, including protein degradation and gene silencing. Once these multipotent 
progenitors arrive in the thymus, they will no longer receive Notch ligand signals from 
thymic stromal cells. When T cells are in shortage within the mammal, the cellular activities 
of POFUT1 may be increased for enhanced Notch1 downstream signaling. Thus these cells 
will have more Notch1 receptors that would increase the chances of binding to their ligands. 
Once they find the Notch1 activating ligand, they will bind well and quickly induce 
intracellular cleavages. Then the chance of this progenitor cell differentiating along the T 
lineage is greatly enhanced.  
Other modulators than POFUT1 can regulate this process as well. For example, 
Fringe enzymes are famous in their regulatory roles related to Notch1 signaling (274). 
Mammals have three different Fringe enzymes, Lunatic Fringe, Manic Fringe and Radical 
Fringe (275). Among them, neither Radical nor Manic Fringe were thought essential for 
development in any mouse tissue (274). Multipotent progenitors over-expressing the 
Lunatic Fringe gene were inclined to adopt the B cell fate within the thymus other than T 
cells (276). Increasing the expression of the Lunatic Fringe in multipotent progenitors may 
reduce its ability to be a T lymphocyte during competition (277). Lunatic Fringe deficient 
mice have been made independently by Jackson Lab (278) and Randy L. Johnson’s lab 
(279). However, there is a discrepancy between the two mouse models. Female Lfn(-/-) 
mice from Johnson’s lab were all not fertile, due to a disorganized ovarian morphology 
(280). But some of the female mice made by Jackson Lab were fertile as reported (281). It 
is not yet clear why there was such a difference between two mice similarly targeted during 
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genetic engineering.  Moreover, there has not yet been any report of thymic abnormalities of 
the Lfn(-/-) mice from either lab yet. It is not known whether Lunatic Fringe is dispensable 
for thymocyte development. 
In summary, our studies have concluded the important roles of fucosylation in the 
regulation of signaling pathways and programmed cellular development. These functions of 
fucosylation had not previously been discovered. Our FX(-/-) mouse model greatly 
enhanced our knowledge in fucose biology and has explored a new field in thymocyte 
development. There are still a few key things left to investigate. The T cell progenitors are 
still thought to have multiple possibilities (216). It is not clear yet how Notch1 gene is 
regulated. Upstream of Notch signaling was not extensively focused yet. Further, Notch 
signaling talks with other signaling pathways forming a very complicated network (282, 
283). It will be very interesting to explore the functions of fucose in regulation of this 







Figure 5-1: Proposed regulatory feed back in T cell 
development via POFUT1. Left panel shows the situation of 
T cell generation. Right panel shows when T cells in peripheral 
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